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Zusammenfassung
Die vorliegende Arbeit konzentriert sich auf Unsicherheiten, die entlang des Verlaufs der
externen Strahlentherapie auftreten.
Zunächst wurde getestet und beurteilt, ob die Qualität der Detektoren, die verwendet
werden, um Unsicherheiten und deren Gründe zu analysieren und um zu entscheiden, ob
ein Plan akzeptabel ist oder nicht, ausreichend genug ist. Für den ausgewählten Detektor
wurde die Winkelabhängigkeit untersucht und ein Kompensationsverfahren vorgeschlagen.
Die Fähigkeit von ausgewählten Planungssystemen, reproduzierbare Behandlungspläne
unter klinischen Bedingungen zu schaffen, wurde durch die Anwendung mehrerer Defi-
nitionen von Komplexitäts-Metriken ebenfalls untersucht.
Ein wesentlicher Teil dieser Arbeit widmet sich der Einführung zweier neuer komplemen-
tärer Software-Tools, die mit TomoTherapy-Einheiten, unter Verwendung der eingebauten
Detektoren, angewendet werden können. Diese Tools ermöglichen es Benutzern, die Haup-
tursachen für Behandlungsfehler zu identifizieren und zu klassifizieren.
Darüber hinaus veranschaulichen wir, wie diese Programme genutzt werden können, um
adaptive Strahlentherapie in der klinischen Routine zu implementieren, indem die Infor-
mationen genutzt werden, um die Maschinenleistung zu bewerten und anatomische Verän-
derungen zusammen mit ihren dosimetrischen Einflüssen zu untersuchen, sei es für einzelne
Fraktionen oder kumulativ für die gesamte Behandlung.
Abstract
This work is dedicated to study the uncertainties occurring along the course of external
beam radiation therapy.
At first it was tested and assessed whether the quality of the detector systems used to
analyze uncertainties, as well as the rationale to decide if a plan is acceptable or not, is
sufficient. The angular dependency was investigated for the selected detector system and a
compensation method is proposed. The capability of selected TPS to create reproducible
treatment plans in clinical conditions was examined as well by applying multiple definitions
of complexity metrics.
A major part of this thesis was dedicated to introduce two new complementary software
tools to be used with TomoTherapy units. These tools allow users to identify the leading
causes for treatment failures using the built-in detector systems.
Furthermore, we illustrate how these tools can be implemented in an adaptive radiotherapy
framework by using their information to assess machine output and anatomical changes
together with their dosimetry influence on the therapy outcome of a single fraction or
cumulatively.
Such methodical studies of the occurring uncertainties and their implications contribute
substantially to the quality of treatments in radio-oncology centers.
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Chapter 1
Radiation oncology and its
uncertainties
Soon after the discovery of x-rays by Wilhelm Conrad Röntgen in 1895, first medical ap-
plications of ionizing radiation were implemented leading to the first scientific publication
related to radio-oncology in March 1897 (Freund (1897)).
Today, cancer is one of the leading causes of death in the world with about 14 million
new cases per year and an expected increase of 70% in the coming 20 years (World Health
Organization (2008)). New treatments are being developed while current techniques are
constantly improved to ensure the best clinical outcome for each patient, to reduce the
number of fatal cases, and to improve the quality of life after cancer.
Along with surgery, chemotherapy, and lately gene therapy, external beam radiotherapy is
one of the main therapeutic approaches to treat cancer. The basic principle is the same
throughout all applicable modalities: High energetic particles are projected towards the
cancerous tissue in order to cause microbiological damage, e.g. strand breaks in the DNA,
inducing apoptosis, a programmed cell death within our immune system. The goal is to
eradicate the degenerated cells while sparing the surrounding healthy tissue. The latter
poses a certain challenge, since ionizing radiation does not distinguish between normal and
tumor tissue. On the one hand, it is vital to apply a sufficient dose to the target volume
to stop uncontrolled cell growth. On the other hand, radiation must be applied as locally
as possible reducing the dose to organs at risk (OAR) to avoid complications such as sec-
ondary cancers. A good compromise with little trade-offs needs to be found.
Although modern techniques provide good solutions to deliver a homogeneous and con-
formal dose distribution within the tumor, they cannot assure a 100% smooth progress of
the treatment without any risks. Indeed, multiple uncertainties persist along the complete
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treatment course, as illustrated in figure 1.1. The consequent errors influence the final
result. In the best case scenario, the occurring errors might compensate each other, but in
the worst case, they will add up. This may cause either overdosage - leading to side effects
up to irreversible damage and death- or underdosage - leading to a possible relapse of the
patient.
Imaging for planning
(e.g. kVCT, MRI)
Treatment Planning
Patient set-up
Imaging for set-up verification
(e.g. CBCT, DRR)
Application of radiation
Treatment verification
(In-Vivo dosimetry)
Conversion from electron 
densities to hounsfield units
Anatomy changes between 
planning CT and treatment, 
subjective delineation by doctors, 
approximative dose calculation 
wrong plan selected, wrong 
patient is responding to call
wrong calibration of imaging 
device
anatomy change, patient 
moving, patient breathing, wrong 
calibration of the machine, 
anomaly in the machine output, 
scatter radiation
Delivery Quality Assurance
uncertain positioning of 
phantom/ detector, angular 
dependencies of detectors, 
calibration of detectors, 
modulation of beams
Figure 1.1: The chain of radiotherapy (left) influenced by numerous uncertainties (right).
The in-vivo dosimetry (IVD) is greyed out, since it is not applied by every center or with
every technique.
National and international organizations and institutions, such as ASTRO, AAPM, and
EFOMP, have issued guidelines offering solutions and standard protocols in order to take
into consideration the uncertainties at different levels of the treatment chain and to reduce
the number of resulting errors.
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At planning level, safety margins were introduced to mitigate the influence of small motion
and anatomical changes. The first structure in the target area is the gross tumor volume
(GTV), which is the actual size of the degenerated tissue visible on the scan. Knowing
that the tumor has microscopic extensions not visible on the classical CT scan, an extra
margin called clinical tumor volume (CTV) is added surrounding the GTV. Considering
uncertainties due to statistical changes, e.g. patient’s anatomy, an additional margin is
created called planning tumor volume (PTV). Lately, another margin - called the internal
treatment volume (ITV)- has been introduced to account for tumor motion, for example
In lung cases.
In order to control the magnitude of uncertainties related to technical issues, for example
the statistical fluctuation of the linear accelerator output and the progressive depletion of
the electronic and mechanical parts. Several recommended quality assurance procedures
are legally imposed, which ought to be done daily, monthly, and yearly (Klein et al. (2009)).
At delivery level, different technological advances have allowed to reduce uncertainties, such
as imaging for patient positioning and tracking for patient motion. In addition, In-vivo
dosimetry (IVD) verifications can be performed to control the quality of the treatment.
Due to its benefits and capability of detecting both patient and machine related errors,
IVD is enforced by law in numerous countries, e.g. in France (Institut National Du Cancer,
(2008)), Sweden, Denmark, Norway, and the Czech Republic (Autorite de surete nucleaire
(2014)).
Thanks to the additional information obtained by such techniques as IVD, a new approach
of controlling the treatment quality was developed: Adaptive Radiotherapy (ART). In on-
line ART, the treatment is verified and modified during the radiation delivery, whereas in
oﬄine ART, the delivery is assessed in between fractions and the remaining fractions will
be adapted if necessary to reach the clinical goals.
The above mentioned procedures and the cumulated experience have given a certain assur-
ance in the control of uncertainties, at least in the case of classical treatments. However,
new techniques and technologies are developed to provide better treatment by increasing
the accuracy and precision, i.e. the efficiency, of treatment delivery. By implementing new
approaches, additional and yet unaccounted uncertainties are introduced, which need to
be addressed.
This work studied such uncertainties that have not been accounted for at a state-of-
the-art equipped center for radiotherapy.
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Chapter 3 is thus focusing on the reliability of the measuring equipment on which as-
sessments of uncertainties, the machine quality, and the technical capability of treatment
delivery is being based. The investigation is focusing on using and correcting the angular
dependency of a 2D detector in combination with rotational treatment techniques.
Chapter 4 is focusing on the planning software and its influence on the uncertainties and
errors in radiotherapy by conducting a retrospective study on the level of complexity of
rotational plans introducing several definitions of complexity metrics.
Furthermore, a new framework of In-Vivo-Dosimetry in TomoTherapy is introduced in
Chapter 5, which might be used in a practical approach to implement adaptive radiother-
apy. Considering figure 1.1, we are thusly investigating uncertainties at three principal
milestones of a radiotherapy treatment: the quality assurance before the actual treatment
delivery, performance of the linear accelerator during the delivery, and the verification of
the delivery’s quality retrospectively.
4
Chapter 2
Basic Principles of Radiotherapy
The basic principles and physics that serve as a foundation of medical physics in external
beam radiotherapy will be discussed briefly in this chapter, starting with the creation of
ionizing radiation and ending with the provoked microbiological effects and how it is used
for medical purposes.
The interested reader is recommended to the following literature for more detailed infor-
mation on basic principles of radiotherapy and radiobiology: Podgorsak (2005), Hall and
Giaccia (2011), Khan (2009).
2.1 Ionization
The easiest approach in creating ionizing radiation is the use of radioactive isotopes with a
long half-life. The element normally used in external beam radiotherapy is Cobalt 60 with
a half-life of 52714 days (Khan (2009)) and a decay energy of round about 2.824 MeV with
peaks in the gamma emission spectrum at 1.17MeV and 1.33MeV (Chofor et al. (2007)).
First medical applications placed sources of 60Co in a holder just above the patient.
Although 60Co machines are still in use today, mainly in regions with a low GDP; most
treating centers switched to linear accelerators. Their development allowed for a more
compact design and thus affordable in price and housing for clinical centers.
The advantages over cobalt machines are the availability of higher and varying energies,
different particles, photons and electrons, and the increased control of the radiation output,
since it could be shut-off by pushing a button. That is possible due to the fact that their
principle of creating radiation is not different to the classical x-ray tube:
Electrons from a source are being accelerated by oscillating electrical fields and are then
guided towards a high Z material, e.g. tungsten. Penetrating the target, electromagnetic
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interactions occur, such as deceleration of the electron (Bremsstrahlung), excitation of the
target’s atoms, which then fall back to their basic state (characteristic radiation), creating
high energetic photons.
2.2 Biological Effects and Physics
When photons enter the tissue several energy dependent interactions with matter take
place. The photon-effect dominates with lower energies, as the Compton-effect does with
medium energies, and the pair production does with higher energies. For therapeutic
energies (6-15 MeV) and human tissue, the Compton effect is the most important one (ct.
figure ??). That is why the energy received increases at first penetrating the tissue, since
scattered electrons and photons are being produced creating a particle avalanche.
After a certain energy dependent depth an electronic equilibrium is achieved and the
energy received decreases following the law of Lambert-Beer:
I(x) = I0 · e−µx (2.1)
Where I(x) is the intensity at the depth x, I0 the intensity before entering the matter and µ a
material specific attenuation coefficient. In order to quantify "intensity", it might be useful
to introduce the official unit being used in radiotherapy: the dose. Generally speaking, the
dose is defined as the absorbed energy per mass unit:
D = ∆E∆m = −
1
ρ
~∇~Ψ (2.2)
ρ is the electron density, Ψ is the fluence, number of particles intersecting a certain area,
and ∇ is the nabla operator. The unit of dose is J/kg defined as Gray (Gy).
The higher the dose, the higher is the absorbed energy. This energy can lead to strand
breaks in the DNA or the creation of free radicals poisoning the cell by breaking up the
phosphorous backbone of the DNA helix. These effects aim at one goal: inducing the
programmed cell death of the immune system, called apoptosis and other mechanisms.
Due to the degenerated state of the tumorous cells, the repair mechanisms are not as effec-
tive as with healthy tissue; hence, radiation is an efficient method to diminish the tumor.
Since it is unavoidable to intersect normal healthy tissue, the difference in repairing ef-
ficiency is exploited by dividing the total prescribed dose to smaller amounts. By that
fractionation, the tumor matter reduces, while the normal tissue can repair itself.
Other biological effects can also be used, for example the oxygen enhancement. Giving the
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patient pure oxygen before the treatment leads to a fixation of the radiation damage, since
free radicals of oxygen are creating bonds with the fracture of the DNA strand. Of course,
this applies in general to tumors, who can have different oxygenation levels depending on
their type of tissue.
2.3 Medical Application of ionizing particles
There are two main usages of ionizing radiation for medical purposes. One started already
with their discovery by Wilhelm Conrad Röntgen, who saw that x-rays can traverse tissue,
thus allowing imaging of biological structures. This feature is still used today in computer
tomography (CT) and "normal" 2D x-ray images.
The second usage is radiotherapy. In early clinical linear accelerators (LINAC), the pro-
duced radiation was being collimated to a square field covering the area of the tumor
delineated in the CT. Today, this technique is called "conventional radiotherapy". This led
to the irradiation of larger volumes of healthy tissue in the vicinity of the tumor. The only
way to avoid this was to adapt the shape of the beam to the form of the target tissue.
That is why the "3D conformal radiationtherapy" was developed. Using this technique the
unwanted radiation is being blocked by massive lead blocs and later by a device called
multi-leaf-collimator (MLC). It consists of several movable plates of absorbing materials
allowing to spare the organs at risk.
Following the evolution in computer technology, more complicated scenarios could be cal-
culated in applicable time. That is why a new technique was developed, which considered
the three dimensional extend of the tumor, the position of OARs to be spared and still
create a homogeneous dose distribution within the tumor volume. For this technique, one
needs to divide the beam into many several subbeams, called beamlets. Each beamlet can
now receive a certain weight or proportion of the dose given by the LINAC from its par-
ticular angle. One needs to apply several irradiated surfaces having different shapes from
the same angle to achieve this weighting procedure in reality. In doing so, one is able to
modulate the intensity of each beamlet by irradiating its area several times or only once.
Each irradiated surface contributing to the same beaming angle is called a segment. Due
to the procedure’s theory, the technique is called Intensity Modulated Radiationtherapy
(IMRT). Applying several beams with several segments leads to a high tumor conformality
while sparing critical organs.
Using IMRT for several years, the idea came up to use more beaming directions. The
advantages are to spread the dose in order to spare the OARs even more, since parts of
them receive smaller amounts of radiation. The problem was that accelerating the LINAC:
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driving it to the next position, decelerate it to a full stop, applying irradiation, and again
accelerating took too much time. The next step then was to get remove the "step’n’shoot"
procedure, applying the radiation while the LINAC is moving. The so-called Volumetric
Modulated Arc Therapy (VMAT) is exactly doing this. Basically, it is a 178 beam IMRT,
where each beam consists of only one segment.
Advantages are the lower dose to the OARs and the plans are faster in application than
normal IMRT plans. A single arc VMAT plan can be irradiated within two minutes, while
the same plan quality in IMRT might take up to twelve minutes.
The increased speed brings several advantages with it. In a shorter time, more patients can
be treated, allowing more people to be helped with their disease. Furthermore, it is better
for the patient, since he or she has to lie down in an uncomfortable position for a shorter
time. This additionally contributes to mitigating the uncertainty of patient positioning,
since the patient does not start moving too much undergoing irradiation. Additionally, po-
tential errors like choosing sub-optimal beam angles are being avoided, since the complete
circle is used to deliver the planned radiation.
Figure 2.2: Comparison of the three techniques. The arrows indicate the intensity. On the
left the 3D conformal radiotherapy with three equally weighted beams. In the center IMRT
using the same three beams but varying the intensity to spare the OAR (green structure).
On the right VMAT, one rotating beam with different intensities.(Hofmann (2011))
Another approach to deliver dose to a target volume was to use different particles.
The first successful implementation is protons. Due to their electrical positive charge
and mass, they produce different effects while interacting with the penetrated matter.
The most relevant one is that their depth dose is described by the Bethe-Bloch-Equation,
i.e. the energy transfer is proportional to the inverse particle speed squared. Thus, they
have a low entrance dose sparing the normal tissue and a finite range (ct. figure 2.3),
which is beneficial for OARs behind the target. In analogy, the development of photon
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based radiotherapy, intensity modulated proton therapy, is introduced in clinical routine
applying the same principles as IMRT, only with protons.
Figure 2.3: Comparison of the depth dose curves of x-eays and protons. c©Proton Therapy
Center.
Additional advantages like an increased biological effect lead to the interest in using
heavier ions, e.g. carbon or oxygen (Dokic et al. (2016)). However, new and additional
uncertainties were introduced with these particles; this issue will not be further elaborated
since this work’s focus is not on particle therapy.
All the presented approaches have in common that the plan is based on a certain central
point, called isocenter, around which the LINAC is moving and the rotation is taking place
in the same plane of this point, thus limiting the beaming directions and the degrees of
freedom. One of the latest innovations in external beam radiotherapy is removing these
constraints. It synchronizes the machine performance with the movement of the treatment
couch and is called 4Pi (Dong et al. (2013)). The first results show a good conformal dose
distribution within the target volume while better sparing the surrounding OARs.
2.4 Uncertainties and errors in radiotherapy
The development of external beam radiotherapy as described above aims at increasing the
efficiency of irradiating target volume. These highly precise techniques depend on the fol-
lowing presuppositions: the optimal patient positioning, the coincidence of the anatomy
and the images recorded by planning CT, flawless performance and output of the acceler-
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ator, and the precise delivery of the calculated plan. But these factors are influenced by
fluctuations and additional human failures. That is why it is concluded that an error must
have happened when the delivered dose differs considerably from the calculated one. Such
errors are subdivided in (van Herk (2011)):
• systematic errors
• statistical errors
• gross errors
2.4.1 Statistic and systematic errors
Statistic and systematic errors are inevitable and might be predictable or not. Their
frequency and amplitude need to be evaluated, controlled, and limited. Predictable errors
are quantified as the variability of the system being within the tolerance intervals of the
applied method. The interval, in which unpredictable errors occur, is called uncertainty
and can be numerically described by the standard deviations. The major uncertainties
present in external beam radiotherapy are:
• Motion related uncertainties. The patient’s anatomy is changing all along the treat-
ment course and even during radiation delivery, due to, e.g. respiration or different
amounts of bowel gas. As a result, the anatomy is not corresponding any more to
the one of the planning CT, which is only a snapshot showing not moving structures.
• Patient positioning uncertainties. The patient has to be set up in the same position as
in the planning CT. It is simply not possible to exactly reproduce the same position
every day with the necessary precision. Safety margins are often used to compensate
this issue.
• Uncertainties in contouring the structures in the planning CT, e.g. a misarranged
definition of the target volume.
• Uncertainties of the accelerator.
• Errors in treatment planning and its delivery.
These uncertainties include two types of errors: systematic (initial patient positioning,
organ segmentation, machine output) or statistic (motion, daily patient repositioning).
Systematic errors affect the complete treatment. For example, the tumor volume was
10
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contoured too small on which the whole plan and dose calculation is based or the system-
atic fluctuation of the machine output present at each fraction delivery. For all patients
combined, systematic errors represent a smearing and a tendency. Statistical errors are
anomalies of each fraction, like the small deviations of the patient position on the treat-
ment couch. These punctual errors smear out over the numerous fractions of one single
patient (van Herk (2004)).
The knowledge of systematic and statistical errors, especially of their magnitude, allows to
consider them and to introduce counter-measures during planning and treatment delivery.
Furthermore, safety systems allow, on the one hand, to verify that uncertainties do not
exceed a certain threshold of acceptance, and on the other hand, to control process of
treatment preparation and delivery.
2.4.2 Gross errors
Gross errors can be caused by material failure or human errors. They can be a conse-
quence of being inattentive, intentional, or involuntary violation of existing protocols and
procedures. Among the principle error sources are: issues with the equipment (including
software), maintenance, calibration of the beam, treatment planning system, or even the
parametrization and delivery of the treatment (Institut de Radioprotection et de Surete
Nucleaire (2015)).
These errors might induce complications that can be gross, persisting, or even irreversible.
An underdosage of the target volume decreases the tumor control probability and increases
on the long term the risk of recidivisms. An overdosage can worsen the state of the patient
considerably, causing necroses, ulcerations, bleedings, etc.
A safety report of the International Atomic Energy Agency (IAEA) mentions as well prob-
lems with the calibration, false usage of materials or the absence of adequate materials, and
insufficient training of the staff. It stresses the importance of implementing a surveillance
system at different levels of the treatment course (Agency (2000)).
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Chapter 3
Uncertainties in the QA process:
Assessment and correction of angular
dependencies of 2D detector arrays
The assessment of the errors during any quality assurance verification relies on a previously
measured database and an established standard.
As the Institut Curie, most modern radiotherapy centers use 2D chamber arrays for the
quality assurance procedures. For these verifications, the users rely on the error tolerances
and technical data provided by the manufacturer.
Nevertheless, additional verifications and adaptations of the database to the specific con-
ditions of a radiotherapy center, individual treatment machines, and detectors may reveal
hidden uncertainties. In fact, in the case of 2D arrays, it is vital to consider and verify the
signal stability under changing angles, especially when doing a quality assurance of rota-
tional techniques as with VMAT or TomoTherapy. Thus, it is crucial to verify whether
the obtained results with the used detector are free of such influences, so one can actually
trust the results of the QA verifications.
The angular dependency of 2D chamber arrays is a known issue (Wolfsberger et al. (2010))
and vendors themselves offer solutions for conventional c-arm accelerators (Shimohigashi
et al. (2012)). In the case of the 2D chamber array MatriXX Evolution (IBA dosimetry
GmbH, Schwarzenbruck, Germany) used at the Institut Curie, the solution consists of a
set of correction factors for the angles from 0◦ to 180◦ with a step size of 5◦ in the ranges
of 0◦-50◦ and of 10◦ steps afterwards. In the most critical angles close to horizontal planes
they are measured every 1-3◦.
This observed angular dependency is caused by the different detection efficiency and cross
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section of the chamber depending on the incident angle of the beam. Staying in the ter-
minology of IMRT, one can imagine one bixel entering the active volume of a chamber
orthogonally. Even with several chambers next to each other only the transversed chamber
will fully detect the beam. Keeping the scenario but changing the incident angle to 90◦
the same beamlet will cross several chambers and the measurement will be affected as to
the locality within the phantom.
One of the major problems leading to this effect is that the array and the LINAC are two
independent systems. As such it is not possible to say which snapshot was taken at which
gantry angle with sufficient certainty. In order to compensate this fact, manufacturers
provide a gyroscope that can be attached to the gantry, continuously measuring the gantry
angle and synchronizing it with the measured signals. The software then multiplies the
measured snap with the corresponding correction matrix.
In addition, most vendors offer water equivalent phantoms into which the array can be
inserted. Due to the geometry of the phantom the angular effects could be reduced (ct
figure 3.2).
However, this modus operandi is not applicable in the case of DQAs performed with a
MatriXX on a TomoTherapy unit. Due to the closed construction of such a unit (ct. figure
5.3) and the 360◦of rotation, no device can be attached to the rotating gantry.
In this section an alternative workaround is proposed based on archived information in the
treatment plan file.
3.1 Materials & Methods
3.1.1 2D detector array
As previously indicated, the 2D ionization chamber array is one of the most used devices
in external beam radiotherapy treatment verification. Its advantages, amongst others, are
the linear response of the chambers, independence on the hardness of the radiation, and
as passive response detectors no extra process is necessary to obtain results. The used
detector was IBA’s MatriXX Evolution consisting of 1020 ionization chambers arranged
on an equally spaced 32x32 grid with a center-to-center distance of 7.62 mm. The missing
four chambers at the corners are virtually replaced by means of linear extrapolation by
the vendor’s readout software. A 100% covering dose distribution is achieved by linear
interpolations between neighboring chambers.
These chambers are air-vented and possess a minimal 20ms read-out time. Their diameter
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is 4.5mm and with a height of 5mm creating a measuring volume of 0.8cm3.
If needed a gyroscopic sensor (ct. figure 3.1)can be attached to the Gantry. By that the
corresponding angle of each measurement snapshot, hereafter called snaps, can be recorded.
The interval between two snaps can be adjusted by the user and is defined as the sample
rate. The rate throughout this work is set to 500ms. If necessary the snaps can be exported
as txt-files and even be re-imported.
Figure 3.1: On the left the MatriXX detector inserted into the Multicube phantom (a)
is shown. The compatible attachable gyroscopic sensor for determining the gantry angle
is depicted on the right(b). Under the gyroscope the MultiCube (c) is shown without the
MatriXX. c©Shimohigashi et al. (2012)
In order to gain electronic equilibrium in the measuring plane and to reduce disturb-
ing back scattering from the penetrating radiation the array can be inserted into a cubic
phantom called MULTICube. It is made of a special plastic having the same electronic
density as water, thus being easier to be considered in dosimetric calculations. Publica-
tions indicate that its design (ct. figure 3.2) is minimizing the angular dependency of the
detector as well (Xu et al. (2010)), which will be analyzed later in this thesis.
The MatriXX is connected to the software OmniPro I’mRT (v1.7.0021), which was also
used to compare the corrected and uncorrected measurements.
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Figure 3.2: The multicube phantom with the MatriXX detetctor inserted is shown on the
left. The right image demonstrates the same phantom with a setup allowing the insertion
of a film without having an air gap. (IBA Dosimetry GmbH (2009))
The background was measured directly before starting each measurement to account
for signal noise from, e.g. cosmic radiation, so that it could be subtracted immediately.
Additionally, a warm-up time of 15 minutes was considered.
3.1.2 Film dosimetry
2D arrays like the MatriXX are successors of older 2D dosimetric measuring tools but still
possess certain disadvantages. The two most relevant points are the angular dependency
and the spatial resolution caused by the finite dimensions of the ionization chambers. That
is why, despite their long history, passive detectors like radiochromic films are still being
used, especially for small field dosimetry where other detectors do not perform well. Hence,
it was decided to use results obtained with film dosimetry as a reference.
The chemical composition of the thin films is reacting with, e.g. ionizing radiation, lead-
ing to the creation of polymers that become opaque. The opacity is proportional to the
dose received, although it is not in direct linear correlation. For that reason, a so called
calibration curve needs to be measured. The curve is measured by irradiating a film with
several known doses, so that one is able to assign a certain optical density to a specified
dose (ct. figure 3.3).
Today’s EBT3 films, also called gafchromic, are self-developing films that don’t need chem-
ical processing like their predecessor the EBT1. Nevertheless, it is important to introduce
a specific protocol due to the chemical reaction, and as such the darkening is taking place
several days until it stabilizes.
In this work two different protocols were used due to an installation of a new scanner:
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1. The films were scanned 18 hours after irradiation, like the calibration curve. Due
to the inhomogeneous light distribution of the scanner lamp, the films were always
digitalized in the same orientation as the calibration. Additionally, the films were
placed in the center of the flatbed, were the most homogeneous light was found.
2. Caused by the installation of a new scanner, a new calibration curve was created
based on films that were scanned 16 hours and 30 minutes after irradiation. Thus,
the measuring protocol was adapted accordingly.
The scanner used with the first protocol was an Epson 3000 and for the second one an
Epson Expression 11000XL. Both are usual flatbed scanners and their scanned images are
saved in the TIFF format. The evaluation was done with the software FilmQA Pro version
v4.0.50399.34122. It can import the scanned images and helps to evaluate the results.
(a) Scanned film (b) Profile in longitudinal direction
Figure 3.3: Example of a calibration measurement. The film was irradiated with different
field sizes and different doses, thus creating a 2D projection of pyramid. The square at the
center received the most dose as it is being irradiated three times and then going outwards
the dose decreases.
The biggest disadvantage of films is the increased workload even with self-developing
chemicals. One still has to scan each film after waiting for the time as previously used
for the creation of the calibration curve. In addition, you need to recalibrate the dose-
to-optical-density curve for each new badge of films, since small changes in the chemical
composition might have a non-negligible influence on the darkening process.
3.1.3 Gamma analysis
One method to classify the quality of a dose delivery is widely used in radiotherapy QA:
It is called gamma analysis (Low et al. (1998)) and compares the actual delivery to the
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planned dose distribution. Being aware that a dosimetric deviation can be created by a
slight misplacement a gamma analysis is considering the dose at a given point within its
environment. That means if at the investigated point the expected dose is different to
the planned one and only slightly shifted by a few millimeters, it can still pass the test
criterion. The gamma criterion is specified by two values: the dose difference and the
distance to agreement, both usually noted like 2%/2mm. It implies that a dose difference
of 2% within a 2mm radius of the analyzed point is accepted.
Since there are thousands of pixels to consider in a dose distribution, it is stated that a
certain fraction of the pixels, e.g. 95%, should fulfill the criteria. This value is usually
called the passing criterion.
Figure 3.4: Example of a gamma report. Shown above are the planned dose distribution
(left) and the measured one (right). In the lower left corner is a summary showing how
many pixels in total were analyzed and how many of them passed (92.73%)/ failed (7.27%)
the criterion in percent. The applied criterion is shown below in the box "GAMMA CON-
DITIONS". 95% of the investigated pixels should have a dose difference lower than 3%
within 3mm. On the lower right is the corresponding visualization of the analysis. The red
areas mark the failing pixels and the green the passing ones. The uncolored areas have a
gamma value below 0.5.
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Due to the wide acceptance both, OmniPro I’mRT and FilmQA Pro, provide the possi-
bility to calculate a gamma analysis. Thus the passing rates will be compared to evaluate
the results of the correction method. The passing criterion is set to 95% for a gamma
criterion of 3%/3mm.
3.1.4 Symmetric response of the detector and qualification of the
angular dependency
A preparatory test was conducted to exclude the influence of a potential intrinsic asym-
metry of the 2D detector. The test was performed on a Varian 2100 C/S linear accelerator
with an energy of 6MV and a dose of 100MU for each field. The field size was set to
40cmx40cm in isocenter to cover all 1020 chambers.
The MatriXX was inserted into the MultiCube phantom to account for the build-up effect
and backscatter radiation and to recreate the setup of actual QA measurements. The field
was then irradiated from various gantry angles: 0, 60, 70, 80, 85, 90, 95, 100, 110, 130,
and 145. These angles were completed by their mirrored values to test the symmetry.
The stepsize was decreased in the interval (80,100), since it is expected to find the biggest
angular effect at these angles.
3.1.5 Influence on the measurements of the divergence of the
beam
Next, it was tested whether the influence of the gantry angle applies to all chambers in the
same magnitude, as it is proposed by some commercial solutions. Considering a homoge-
neous environment with a uniform dose distribution, the angular effect was quantified by
dividing the measured value of every single chamber by its value as calculated by the TPS.
Showing all 1020 graphs of the obtained results would not be helpful to understand the
mentioned problem. That is why the following eight chambers were chosen to represent
the results, since they show the two extremes in terms of the effect created by the beam’s
divergence:
• The four central chambers (please note that the MatriXX has no central chamber),
denominated P1-4.
• The four corner chambers, P5-8.
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The exact coordinates of the eight points with reference to the MatriXX’s center
are: P1(-0.38,0.38), P2(0.38,0.38), P3(0.38,-0.38),P4(-0.38,-0.38) and P5(-12.19,12.19),
P6(12.19,12.19), P7(12.19,-12.19), P8(-12.19,-12.19)
3.1.6 Correction Factors
In order to assess an angular correction it is necessary to know its magnitude. Having
shown that it is important to consider the position of the chamber in relation to the
field, two separate sets of correction matrices were investigated. These sets of matrices
result from two different methods of creating the correction factors: either empirically by
comparing the array’s measurement to a reference detector or by calculating the detector
response, e.g. with Monte Carlo simulations.
3.1.6.1 Obtaining correction factors using cross-calibration with film dosime-
try
Based on the fact that the vendor’s correction matrices for the used MatriXX model apply
only one factor per angle for all 1020 ionization chambers, ignoring the beam’s divergence
for off-axis chambers, it was decided to create a new set of matrices obtained by cross
calibration with EBT3 Gafchromic films (ct. chapter 3.1.2).
To achieve this goal a protocol was developed in which static gantry procedures of a
TomoTherapy unit were created at various angles. The same procedure was then irradiated
twice: Once each on the MatriXX detector in the MultiCube and as well as on the film
with its special insert to ensure comparability of the results. The insert is filling the air
gap, since a film is thinner than the 2D array. In addition, the insert ensures that the film
is at the same height as the measuring plane of the MatriXX’s ionization chambers. The
correction factors are obtained from the superposition of the MatriXX’s results and the
EBT3 results by applying:
CFij =
DMatriXXij
DFilmij
(3.1)
Where i and j are row and column indexes of the center position of the chambers and
D the measured dose. In order to create a full set of correction matrices and a better
approximation of the needed correction, the obtained results were mirrored and used as
fixing points for linear interpolations. By doing so a step size of 1◦ could be reached, i.e.
a set of 360 correction matrices was created.
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3.1.6.2 Using the manufacturer’s correction factors
The official CFs were included in the study although they neglect the effect on the off-
axis chambers and were created solely for open fields (20cmx20cm). Nevertheless they
are accepted as an official solution applicable in a clinical environment. Their values are
presented in figure 3.5. They were calculated by modeling the chamber responses in Monte
Carlo simulations.
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Figure 3.5: Correction factors extracted from the matrices as provided by IBA to be used
with the gyroscopic sensor on "conventional" linear accelerators.
As in chapter 3.1.6.1 the provided factors are mirrored and linear interpolated to in-
crements of 1◦.
3.1.6.3 In-House developed correction algorithm
The first and main problem is to find the gantry angle corresponding to each snap, since
the gyroscope cannot be used. Thus the presented approach is introducing a virtual gy-
roscopic sensor. The created algorithm uses the recorded plan data of the DQA which
is stored in a XML file and can be retrieved by archiving or exporting the patient files.
The necessary information is to be found in the personalized file with the scheme FAM-
ILYNAME^FIRSTNAME_patient.xml. Opening the file it is important to search the
first "Treatment" position, otherwise the information of the MVCT for positioning will
be loaded, which is different in its characteristics to the ones of the treatment e.g. less
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projections per rotation. In addition, it is necessary to check if the process has finished
successfully, otherwise the information will be false or incomplete. The status is indicated
by the missing "Interrupted" entry in the "treatmentProcedure". Now the actual infor-
mation can be extracted, namely the "nominalGantryPeriod", "desiredGantryStartAngle",
"deliverTimeSeconds", and "deliverTime100USeconds". The variables are self explanatory,
but it should be pointed out that 100USeconds represent 100µs leading to the total delivery
time in seconds: ttotal = deliverT imeSeconds+ deliverT ime100USeconds · 0.0001.
The gantry speed in ◦/s can now be calculated with −→v G = 360◦nominalGantryPeriod .
The first idea right now would be to delete all first zero-snaps, since the measurement
can be started at any moment independently of radiation being present or not, and assign
the desired gantry start angle to the first snap and then start to count. However, this
approach will probably lead to false results, because the TomoTherapy R© unit is starting
the radiation a few seconds and degrees before this value in order to provide the planned
dose and dose rate at the first saved position. This might lead to a recorded non-zero snap
not being at the programmed start angle.
The gantry angle at which radiation starts is calculated from the gantry angle at which
radiation stops, corresponding to the last non-zero-snap, as shown below:
ϑlastProj = desiredGantryStartAngle+ (ttotal ∗ −→v G) % 360 (3.2)
with % being the modulo operator.
Knowing the sample time of the MatriXX, 500ms in this study case, it is possible to count
backwards until the snap of the desiredGantryStartAngle has been reached. It can be found
by calculating the number of irradiated snaps: Sirr = ttotalSampletime and counting backwards
as well.
Now, the software is ready to correct the measurement by extracting the 32x32 chamber
signals exported in TXT format by the evaluation software. These values are then mul-
tiplied with their corresponding correction factor and again exported in TXT format, so
they can be re-imported to OmniPro I’mRT for further analysis.
The flowchart summarizing the program is shown in figure 6.1.
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Figure 3.6: Workflow of the angular correction using a 2D detector array.
In order to test this approach, eleven clinical cases were chosen and re-irradiated. The
gantry angle of each dose projection was extracted from the Tomo-System directly after
the application of the irradiation. The data was then analyzed and the angles of the projec-
tions at 0%, 25%, 50%, 75%, and 100% of the process of the plan extracted and compared
to the values calculated by the angular distribution algorithm (ADA).
28 clinical cases with the following treatment sites were tested to verify the complete algo-
rithm, including the correction factors: one opthalmologic, two anal canal, three rectum,
two lung, two lumb (leg), two breast, seven gynecological, and nine head and neck cases.
The selection was done arbitrarily among the newest DQAs. It was decided to incorporate
more gynecological and head and neck cases, since they are usually more complicated to be
irradiated. Due to their complexity a high modulation is to be expected and as such a high
number of beaming directions, which should increase the effect of the angular dependency.
The results of the correction will then be compared to the uncorrected ones using Om-
niPro I’mRT by applying the above mentioned gamma criterion. In order to exclude false
negatives or false positives, the cases with the biggest differences in passing rates were
remeasured using radiochromic films as a detector to have the corresponding reference
value.
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3.2 Results
3.2.1 Symmetric response of the detector
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Figure 3.7: Results of the test if the MatriXX has intrinsic asymmtries for the four central
chambers.
The measurements, as shown in figure 3.7, confirm a sufficient symmetry of the 2D array.
This allows to assume that the structure of the detector itself does not have an influence
on the signal response. Only the peak values at 90◦ and 270◦ show a slightly asymmetric
behavior. It can be explained by the table’s construction and an additional backscatter
plate integrated in the 2D array protecting electronic parts. Alternatively, the factory
array calibration may also play a role.
The obtained result confirm the findings of Wolfsberger et al. (2010) and the actual presence
of the angular dependency.
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3.2.2 Influence on the measurement of the divergence of the
beam
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Figure 3.8: Signals of the four central chambers, P1-P4, (a) and the four on the outer
corners, P5-P8 (b). While P1-P4 have an almost parallel behavior showing that the di-
vergent effect is negligible at these positions; one can see that there is a discrepancy for
P5-P8. One can even determine which chambers are on the same side of the gantry. The
coordinates with reference to the MatriXX’s center are given in cm in the legends.
It can be seen in figure 3.8 that while the four central chambers are responding in a good
symmetry, the four outer signals prove a strong non-negligible effect. Differences in signal
response go up to 16.07 percentage points at 90◦ and 12.43 at 270◦. It can be observed
that the angular influence is stronger in lateral than in longitudinal direction, which can be
explained by the change of the incident angle of the beam when turning the gantry. The
results show that it is necessary to have more than one correction factor for all chambers
per gantry angle to obtain more accurate results.
3.2.3 Correction factors obtained by cross-calibration
The obtained results of the four central chambers are shown in figure 3.9 together with the
vendor’s CFs.
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Figure 3.9: Results of the CFs of the four central chambers obtained by the cross-
calibration with Gafchromic films (solid, orange line) in comparison to the CFs provided
by IBA (dashed, grey line).
The self-created CFs display an interesting behavior. Instead of decreasing in the in-
tervals (0◦, 95◦) and (360◦, 270◦), they are constantly increasing. The minimum of IBA’s
factors had been missed due to our step size indicating that in this range one should mea-
sure in 1◦ increments.
Additionally, the values in the interval (95◦, 270◦) are in average 2.47% higher than the
official commercial correction. The resulting DQA checks, which can be found in chap-
ter 3.2.5.1, showed that the factors lead to lower gamma passing rates than the original
uncorrected measurement.
3.2.4 Angular distribution algorithm
Table 3.1 is showing the results of the Angular Distribution Algorithm’s (ADA) verification
taking the average of all tested cases.
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Table 3.1: Differences between the planned gantry start angle and the recorded value of the
first dose projection, and the recorded gantry angles of each projection and the calculated
ones for the specified point of progress of the treatment. The results show the average of
all test cases including their standard deviation.
Process of the plan [%] ∆θGantryStart[◦] σ∆θGantryStart [◦] ∆θSnap[◦] σ∆θSnap [◦]
0 3.46 0.05 3.42 2.74
25 N/A N/A 46.84 87.21
50 N/A N/A 4.03 3.07
75 N/A N/A 4.09 2.26
100 N/A N/A 3.21 1.05
The differences between calculated and recorded gantry angles match within 4.09◦,
which is slightly higher than the difference of the planned starting angle and the first
recorded gantry position, which is 3.46◦. Additionally, it is smaller than 5◦ and as such
smaller than the distance between two fixing points of our linear interpolation. Keeping
in mind that any angle could be possible, the achieved accuracy is in the range of 1.14%.
Thus, it is assumed that the ADA is working with an acceptable accuracy.
The only erroneous results were obtained with two head and neck cases. One was off by
-165.02◦ and the second one by -170.04◦ at the 25% progress point. A reason for this
behavior could not be found yet. The distribution of the dose projections over all four
quadrants of the circle were similar to the other plans and there was no other value,
e.g. gantry period, dose projections per rotation, gantry start angle, or prescribed dose,
distinguishing these two cases from the rest. It might be possible that the synchronization
progress did not work in these cases due to a problem during the delivery of the DQA.
A bigger sample size in the future might uncover the reason for the failure at the 25%
position.
3.2.5 Application of the angular correction on clinical cases
3.2.5.1 Film based correction factors
Looking at the final results, the apparent differences between the vendor provided factors
and the obtained results from chapter 3.2.3; it was expected that the proposed correction
will constantly lead to lower passing rates. Thus, only a few of the above mentioned cases
were tested to prove that the correction factors obtained by the cross-calibration should
not be used.
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Table 3.2: Results of the DQA measurements corrected with the film based CFs applying
a 4%/3mm gamma criterion. Serving as a comparison the values of the vendor based
corrections are shown as well.
Uncorrected DQA [%] Film based CFs [%] Vendor based CFs [%]
H&N 1 95.97 90.58 99.47
H&N 3 99.05 94.52 99.92
H&N 4 99.88 95.04 99.49
H&N 8 99.38 95.62 99.7
Rectum 1 100 97.87 99.79
Gyneco 2 99.76 80.16 99.53
Canal Anal 1 99.76 85.74 99.43
As one can see the applied CFs result in lower passing rates throughout. In some cases
even to the extent that the plans fail the passing criterion. Even though, the manufacturer
based results show improvements or are in the same range, within 0.5%, as the uncorrected
acceptable results and are shown for comparison in the table as well.
Reasons for the differences will be discussed later on.
3.2.5.2 Manufacturer based correction factors
As shown in figure 3.10 the applied correction with the vendor based CFs produce in general
better DQA results or at least in the same range, i.e. the average difference excluding the
big deviations is 0.05 percentage points. The correction gave worse results only in the case
of Gyneco 6. These results cannot serve as a final proof of whether the presented approach
works successfully or not, since false positives or negatives can be created by the angular
effects.
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Figure 3.10: Comparison of the DQA results uncorrected (grey) and corrected (orange)
for the angular dependency of the MatriXX.
In order to verify which of the results are a better representation of the reality, the cases
with the most pronounced differences were chosen and remeasured using Gafchromic film as
a reference with a newly installed scanner. The results of the control are shown in table 3.3.
Table 3.3: Verification of the DQA results. EBRT3 Gafchromic films served as a reference
to decide which value is to be interpreted as the correct one. The film of leg 2 could not be
analyzed due to an unknown software issue.
uncorrected DQA [%] corrected DQA [%] film DQA [%]
H&N 6 55.16 81.63 84.33
H&N 2 90.56 97.55 97.4
Gyneco 6 92.07 88.97 100
Leg 2 81.49 90.74 N/A
It is difficult to derive a clear conclusion from the verification, since there are only
three interpretable results. For the cases H&N 6 and H&N 2 it is clear that the corrected
measurements match the film DQA’s passing rate very well, whereas for Gyneco 6 the un-
corrected measurement is closer to our reference, although it has a non-negligible difference
of eight percentage points.
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In the leg 2 case it was not possible to load the scanned film into the evaluation software.
It was scanned several times to exclude a corrupted file and remeasured a week later, but
still the software refused to load the image. Since it was a leg case having the primary
dose distribution very far off-axis, it is assumed that the software had problems with the
coordinate system.
3.3 Discussion
The presented approach shows the necessity of considering the angular dependency in QA
processes based on the information obtained with a 2D chamber array, as such as the one
evaluated in this work, the MatriXX. For correcting measurements it is necessary to apply
correction factors to the raw measurements.
Two different sets of CF matrices were tested and compared. The set based on the cross-
calibration with film dosimetry lead to lower passing rates than the uncorrected results.
This is caused by the CFs themselves, which have large differences to the official and com-
mercial available correction matrices. The scanner’s quality might have influenced the
results of the film measurements as the reproducibility of the films was not as expected.
In fact, a later investigation showed that the same film scanned several times lead to up
to 5% difference in signal.
The factors provided by IBA though lead to good results and in general higher passing
rates than the uncorrected measurements. One might be surprised, since the vendor’s CFs
do not consider the divergence of the beam and as such ignoring the effect on the off-axis
chambers. An explanation is the nature of rotational techniques: In order to decrease the
dose to the normal, healthy surrounding tissue a high number of beams is delivered in
small portions leading to small field sizes and as such to small bixels contributing to a
segment. Thus, the divergence is rather small. If the plans consisted of large open fields,
these factors would probably also lead to lower passing rates.
IBA itself noticed that the set of the correction factors need to be improved. The new
generations of MatriXX detectors are delivered with new sets based on Monte Carlo simu-
lations. Due to the different intrinsic structure these are not applicable for older models. A
comparison between corrected and uncorrected DQAs show the same magnitude improve-
ment as our results (ct. figure 3.11).
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Figure 3.11: Angular correction using the CFs provided by IBA with their new detector
generation. (Sekar et al. (2016))
In order to apply the correction factor to the corresponding snap, it is necessary to
know the gantry angle of each snap. An algorithm was developed which is replacing the
physical gyroscopic sensor by a virtual one relying on the machine data from the plan
file. The verification of the ADA shows its capability of accurately determining the gantry
angles of the snaps by counting backwards from the last dose projection.
The only two exceptions were two head and neck cases at the 25% position of the treatment
where both are off by more than -160◦. Although a thorough investigation was launched
the reason for this difference could not be found yet. A bigger sample size might uncover
the distinctive factor of these cases.
The verification of the corrected results with the film detectors serving as a reference
showed a good agreement with our findings which are comparable to the results in figure
3.11.
The major insecurity of the presented approach is still the synchronization of the gantry
angle and the snaps, since the ADA is a theoretical calculation, which cannot consider
deviations occurring the DQA delivery. Thus, it would be better to introduce a system
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that actually can detect the gantry angle of each dose projection. An example of such a
system will be discussed in chapter 5.7.
A positive effect is that stricter gamma criteria might be applied to already detect mi-
nor problems that would have remained undetected without the correction of the angular
effects. A first small study of a gamma criterion of 2%/ 2mm is shown in table 3.4. Canal
Anal 1 is such a case. With a gamma criterion of 3%/3mm the passing rate was 99% for
the uncorrected and 97% for the corrected one. Penalizing smaller changes with the new
gamma criterion, the passing rate is dropping to 76.72% indicating a potential problem.
Table 3.4: Preliminary results of a first sensitivity study if a stricter gamma criterion of
2%/ 2mm might be used after the correction of the angular dependency.
Uncorrected DQA [%] Corrected DQA [%]
H&N1 69.36 83.02
H&N3 88.34 92.66
H&N4 91.03 91.11
H&N7 85.95 88.92
Rectum 1 97.43 92.21
Canal Anal 1 71.1 76.72
Having the reduced uncertainty of angular dependency using a 2D chamber array, it is
possible to further analyze other uncertainties applying this kind of detector.
32
Chapter 4
Uncertainties in VMAT QA and
delivery due to modulation. A
theoretical retrospective review
One of the most popular techniques in modern radiotherapy is VMAT, as discussed in
chapter 2. This technique involves a constant motion of the gantry while delivering an
intensity modulated treatment plan. The delivery of such a plan is highly complicated as
the leaves of the MLC are constantly adapting their shape while staying synchronized to
the beam angle.
Multiple factors have to perfectly interplay to create an acceptable dose distribution. These
parameters, to be adjusted during the treatment delivery, are: the gantry angle, the gantry
speed, the dose rate, the position, the speed of the leaves of the MLC, and lately the
treatment couch position. The change of their values leads to a stronger, more complex
modulation of the dose. The stronger the change of the values, the higher is the modu-
lation of a treatment plan. In comparison to IMRT many additional variables are to be
considered introducing more uncertainties. Only one of these factors malfunctioning could
already lead to a treatment error.
At our center, it was observed in clinical routine that a higher than usual amount of plans
fail the quality assurance check prior to the actual treatment. After excluding the most
typical sources of errors like sharp dose gradients or failure of the measurement chain, it
was suggested that the discrepancies might be due to a high level of modulation. In its
struggle to achieve the planning requirements, the TPS could overmodulate, i.e. calculate a
theoretical plan with such parameters that cannot be achieved in real treatment conditions
within an acceptable tolerance (Kruse (2010), Hanusova et al. (2015)). The modulation
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itself and its constraints are dependent on the used TPS, since each vendor has his own
way of dealing with the plan optimization.
Although the manufacturer has implemented safety algorithms which should theoretically
prevent this from happening (Yang et al. (2015)), this occurrence has been reported in- and
outside our department. However, previous investigations of the phenomenon remained in-
conclusive, since literature is indicating both: the modulation is either affecting the DQA
(Masi (2013)) or not (Celi et al. (2015)). An investigation was launched to officially con-
firm or deny the suspicion for VMAT cases at our center. In the case of confirmation the
implemented tools could be used as a predictive warning system.
4.1 Materials & Methods
4.1.1 C-arm LINACS
Due to their long history and technological evolution allowing for isocentrical treatments,
c-arm shaped linear accelerators are the most used devices to deliver external beam ra-
diotherapy. The accelerators used in this work are a TrueBeam (Varian medical systems)
and a 2100 C/S (Varian medical system). Both machines are capable of delivering rota-
tional treatments, like VMAT. They are operating with different energies for photons and
electrons at various dose rates and are equipped with a high resolution (Millenium 120)
multi-leaf collimator. As the name suggests the MLC consists of 120 leaves collimating
the radiation to the shape of the tumor. The 20 leaf pairs at the center have a width of
5mm and the outer 40 have a width of 10mm. The leaves can move continuously with an
accuracy of 0.1mm.
For our investigations the possible sources of uncertainties are important coming from the
MLC causing low dose radiation due to leakage created by the gaps between neighboring
leaves. It is 1.5%-3.5% between the leaves and 12-28% through a closed leaf pair.
The majority of modern linear accelerators are equipped with electronic portal imaging
devices (EPIDs). They are used to image and check the patient’s position before deliv-
ering each fraction minimizing the positional uncertainty. However they might introduce
a different one. Since the EPID is retractable and adjustable in its position with Varian
LINACS, a small error in its positioning will lead to increased uncertainties during the
treatment delivery. This plays a very important role when an EPID is being used for
in-vivo dosimetry. Small deviations on the vertical axis lead to a different dose response.
The decrease can be described by the inverse-square law (Khan (2009)).
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(a) (b)
Figure 4.1: The c-arm linear accelerator TrueBeam (a) and its 120 millenium MLC (b).
In the lower part of the first image you can see the retractable EPID.
4.1.2 Extraction of the necessary plan data
As described above a lot of different parameters are combined to produce the desired dose
distribution. Some of them do not even share the same physical dimension. It is crucial thus
to conceive an index to classify and quantify the magnitude of the plan’s modulation. This
will constitute a basis of comparability among the investigated plans. It is important as well
to study the modulation from multiple perspectives: statstics, geometrical, dosimetrical,
and a combination of all of them.
The detailed plan components are to be extracted to estimate the modulation of a plan.
In a modern TPS, Eclipse by Varian in our case, this treatment information is stored in
a unified data format called DICOM, which includes the demographics of a patient, the
positioning information as well as the technical plan data like gantry angle, the MLC leaf
position etc.
In the case of VMAT plan files the information is split up in so called control points (CP)
which are usually placed every two degrees of the arc leading to a total number of 178 CPs
for a complete arc of 360◦. An automated algorithm was created in Matlab R©to open the
exported plan file and extract all information affected by the modulation per control point:
• Gantry angle (θG)
• Cumulative meterset weight (CMW) (fraction of the dose applied between two adja-
cent CPs stored as a decimal number between 0 and 1)
• Total dose per arc in Gy
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• Total number of Monitor Units (MU) per arc
• Leaf positions of the MLC in mm
The missing factors can now be easily derived:
• Travel distance for each of the 120 MLC leaves by subtracting the positions of adja-
cent CPs:
dx,travel = Positionx,CPi+1 − Positionx,CPi (4.1)
with x the number of the leaf and i the number of the CP
• Gantry speed (−→v G). This value is neither stored, nor can it be calculated with the
provided information. Nevertheless, in our center the TPS, Eclipse by Varian Medical
Systems, was configured according to the manufacturer’s guidelines to provide a
gantry speed of 4.8◦/s as long as being achievable from a mechanical and dosimetrical
point of view. This gantry speed is the standard for all clinical plans at our center.
The gantry speed per CP can thus be simply and quickly checked before exporting
the DICOM file. So far no deviations from the maximum value could be observed.
• Dose delivered between two adjacent CPs:
D = (CMWCPi+1 − CMWCPi) · total dose per arc (4.2)
• Dose rate (DR) of each CP in MU/minute:
DR = (CMWCPi+1 − CMWCPi) · total number of MU per arc
θG,i+1 − θG,i ·
−→v G · 60 (4.3)
A verification of the values can again quickly be done with the TPS and showed that
the calculated numbers match the original ones by 99% or better.
Different factors influencing the modulation as well as combinations of factors were
tested in order to establish the sources of the observed deviations. Several indexes have
been previously defined, e.g. by McNiven et al. (2010),Webb (2003) or Masi (2013), to
characterize and quantify the modulation of a plan. Additional indexes have been conceived
for the purpose of this study.
For each definition, the correlation between the modulation index and the results of
the DQAs of 121 prostate patients treated by two complete arcs was analyzed. The DQAs
were performed on a IBA MatriXX R© 2D ionization chamber array. The analyses of the
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measurements were done with the commercial software OmniPro I’mRT (IBA). In order
to rule out a systematic error of the LINAC, two patient groups treated at different ac-
celerators were included in the investigation. These LINACs were a TrueBeam (Varian)
and a 2100C/S (Varian). The results of the DQA were investigated in two manners: as a
binary result - passing/failing the 4%/3mm gamma criterion - or in the form of the actual
gamma passing rate.
A test plan was created with Matlab to verify the written algorithms. This plan consists
of a cylindrical dose distribution within a cylindric homogeneous phantom by setting the
MLC leaves to a fixed position of +2.5cm and -2.5cm in the isocenter plane. As such
no parameter contributing to the modulation should change, i.e. constant gantry speed,
constant dose rate etc. The studied modulation factors are being discussed in the following
sections.
4.1.3 Definitions of Modulation Factors
4.1.3.1 Standard Deviation of the Dose Rate
In the case of the VMAT as carried out by Varian Medical Systems, the dose rate varies
from CP to CP, regulating the amount of radiation applied within a certain gantry angle
interval to fulfill the planning requirements. A vastly changing dose rate might be a
good indicator that the plan is too modulated for real conditions. In order to evaluate the
influence of the dose rate variability on the performance of the plan, the standard deviation
of the dose rate was determined for each arc.
σDR =
√
V ar(DR) (4.4)
If σDR = 0, the dose rate remained unchanged, thus unmodulated, the machine output is
a constant number. The higher the standard deviation is the more changes are present,
i.e. the higher the modulation.
The values were confronted to the DQA results, both in binary form and the passing rate,
as shown in figure 4.2.
4.1.3.2 Adaptation of the Definition used with TomoTherapy
The next factor characterizing the modulation was adapted from a definition used for
TomoTherapy units. In TomoTherapy, a modulation index is defined by the maximum
leaf open time divided by the average leaf open time. This definition is, in the case of
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c-arm LINACs, purely geometrical and is calculated per arc. Since the MLC leaves are
not binary as in TomoTherapy units, the definition had to be modified. In analogy to the
leaves being open for a certain time, the maximum irradiated surface of all CPs within an
arc was divided by the average size of the irradiated area of the corresponding arc.
MFtomo =
Amax
Aaverage
|arc (4.5)
where A is the irradiated area.
4.1.3.3 Travel distance of the leaves of the MLC
a) averaged over the whole arc
One of the weakest points in the modulation of a plan is the performance of the leaves.
Indeed in the case of the sliding window technique, the position of the leaves has to rapidly
adapt to the requirements at the next CP. The leaves might therefore need to mechanically
drive fast to a new position with a maximum speed of 3cm/s (Arno et al. (2005)). Although
the optimization algorithm is set up to minimize the necessary travel distance, extreme
scenarios implying extreme modulation levels may require to break a certain limit. Thus, a
new factor was defined to establish the influence of the travel distance of one leaf between
two adjacent CPs of the arc, since the MLC has 120 leaves and one complete arc 178 CPs,
the average and maximum travel distance was taken from all CPs in one arc:
MFtravel,arc =
dtravel,max
dtravel,average
(4.6)
b) averaged over the CPs
In order to verify whether an important movement was overlooked by averaging over the
complete arc, the definition in 4.1.3.3 was applied to each CP and then averaged over all
CPs of one arc:
MFtravel,CP =
dtravel,max,CP
dtravel,average,CP
(4.7)
4.1.3.4 Adaptation of a definition introduced by S. Webb
Supposing that a combination of several characteristic parameters may play an important
role in the modulation, complex definitions of modulation considered, which integrate these
parameters into one single modulation index.
An initial complex modulation index was defined by Webb (2003) for IMRT.
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In IMRT each beam is subdivided into infinitesimal small pieces called bixels (beam el-
ements in analogy pixels). Each bixel has a different intensity composed of numerous
segments. Webb suggested to analyze a beam with n numbers of elements with the bixel
intensity Ip with p=1,2,...,n.
The principal idea is to calculate the integral of the spectrum z(f) of the number of adja-
cent element changes that exceed a certain fraction of the standard deviation of the beam.
Thus the standard deviation σI of the intensity and the dimension of changes between two
neighboring bixels ∆p = |Ip − Ip−1| are to be calculated.
Next, the number of changes larger than a certain fraction of the standard deviation
[Nf,∆p>f ·σI ] is calculated with f=0.01, 0.02,...2. Thus the spectrum is
z(f) =
( 1
n− 1 ·Nf,∆p>f ·σI
)
(4.8)
leading to
MFWebb =
∫ 0.5σ
0
z(f ′) df
′ (4.9)
Like mentioned above, equation 4.9 was initially designed for IMRT. The bixel intensity Ip
has to be slightly adjusted to adapt the definition for VMAT plans. Every control point in
one arc is interpreted as a beam and the programmed field size/ shape is one "giant" bixel,
thus Ip=̂ICP .
4.1.3.5 Definition adapted by L. Masi
A modulation quantification created by McNiven et al. (2010) for IMRT plans was adapted
by Masi (2013) for VMAT plans. This factor is called the "Modulation Complexity Score"
(MCS). Its advantage is the combination of leaf mechanical, geometrical, and dosimetrical
data. As above, in section 4.1.3.4, the adaption was done by interpreting the control points
as an IMRT segment.
The leaf travel information is taken into account by the Leaf Sequence Variability (LSV).
The LSV is based on the difference in position of neighboring leaves relatively to the
maximum possible difference within each CP per leaf bank:
posmax,CP = [max(posn∈N)−min(posn∈N)]leafbank (4.10)
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LSVCP =
(∑N−1
n=1 (posmax,CP − |posn − posn+1|)
(N − 1) · posmax,CP
)
leftleafbank
·
(∑N−1
n=1 (posmax,CP − |posn − posn+1|)
(N − 1) · posmax,CP
)
rightleafbank
(4.11)
with N being the number of moving leaves and pos the position of leave n. The LSV is
1 if the leaves do not move during the application of the plan. The more complex a field
shape is, with bigger changes in the positional change of neighboring leaves between two
CPs, the smaller is this factor.
Next, the complexity of the change of the field shape is included by calculating the Aperture
Area Variability (AAV). The AAV is the area between two opposing leaves normalized to
the maximum area of the leaf pair of the complete arc:
AAVCP =
∑A
a=1(posa,leftleafbank − posa,rightleafbank)∑A
a=1(max(posa)leftleafbank∈arc −max(posa)leftrightbank∈arc)
(4.12)
where A is the number of leaves in the arc. The AAV describes the area of the irradiated
surface of a given control point in the context of all the surfaces defined by the leaves.
Thus, for a square field this value will equal 1. The more the area is different from the
maximum area, the smaller the AAV.
The MCS considers that, in VMAT, radiation is applied during the movement of the
accelerator. Hence, the average values of two adjacent CPs needs to be calculated and be
weighted by the number of MUs delivered between these two CPs:
MCSarc =
I−1∑
i=1
[
(AAVCPi + AAVCPi+1)
2 ·
(LSVCPi + LSVCPi+1)
2 ·
MUi,i+1
MUarc
]
(4.13)
Where I is the number of CPs and MUi,i+1 the number of MU delivered between two
adjacent CPs. The smaller the MCS, the higher the modulation.
4.2 Results
4.2.1 Standard deviation of the dose rate
No obvious correlation could be observed between the standard deviation of the dose rate
and the failing DQAs. The failing and the passing plans present a similar level of dose rate
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variability and some plans with very high variations of the standard deviation still pass.
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(a) Standard deviation of the dose rate vs. the DQA passing rate. Shown are the
MFs of the plan.
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Figure 4.2: Results of the standard deviation of the dose rate in relation to the actual
(a) and binary DQA measurements (b).The red squares in (b) depict the measurements not
passing the gamma criterion. Shown are the MFs of the plan.
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4.2.2 Adaptation of the definition used with TomoTherapy
As in the previous section, the modulation factor was confronted to both the binary DQA
results and the actual gamma passing rates (see figures X and Y). No direct correlation
can be established between the failing DQAs and the magnitude of the modulation of field
sizes.
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Figure 4.3: Adaptation of the Modulation Factor as used in TomoTherapy on the actual
passing rates (a) and the binary DQA results(b). The red squares show the failed DQA
data points of the binary results.
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4.2.3 Travel Distance of the Leaves of the MLC
a) ... Averaged Over the Whole Arc
A comparison to the DQA results in binary form and as gamma passing rates leads to the
observation (figure 4.4) that the failing plans have the same magnitude of modulation as
the passing ones. As before, even the results with the highest modulation are passing the
selected gamma criterion.
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(a) Leaf travel distance averaged over the arc versus the gamma passing rates.
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Figure 4.4: Results of the gamma passing rates (a) of the DQA measurements versus
the travel distance between adjacent CPs averaged over the full arc and the corresponding
binary results (b). The red squares in (b) mark the failing DQAs.
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b)... Averaged over the CPs
The results of the comparison to the DQAs confirm the previous comparisons by showing
(ct. figure 4.5) that failing and passing plans have the same magnitude of modulation.
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(a) Leaf travel distance averaged over CPs versus the passing rates.
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Figure 4.5: Results of the gamma passing rates of the DQA measurements versus the
travel distance between adjacent CPs averaged over the CPs (a) and the binary results (b).
The red squares symbolize the failed DQAs.
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4.2.4 Adaptation of a definition introduced by S. Webb
A comparison against the DQA passing/failing plans (ct. figure 4.6) reiterates the previous
results: the plans in the passing and in the failing groups have similar modulations as
defined by this modulation factor.
MFWebb
10 12 14 16 18 20 22 24 26
G
am
m
a 
Pa
ss
in
g 
R
at
e [
%
]
86
88
90
92
94
96
98
100
MFWebb
Passing Criterion
(a) Adaptation of Webb’s definition versus the gamma passing rate
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Figure 4.6: Results of the gamma passing rates of the DQA measurements versus the
adaptation of the definition given by Webb (2003) (a) and the binary results (b). The red
boxes represent the failed quality checks.
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4.2.5 Definition adapted by L. Masi
Concluding from figure 4.7, there is no clear threshold applying Masi’s adaptation of the
MCS. Most of the failing DQA measurements are again in the modulation range as the
major DQAs passing the gamma criterion. In the published paper one could see a slight
tendency between lower MCS, i.e. higher modulation, and lower passing rates. Since the
created algorithm was verified using the test plan file where neither leaf motion nor change
in the dose rate is necessary the remaining difference is that the publication investigated
single arc plans. These require increased modulation, since they need to create the desired
dose distribution in only one rotation. Furthermore, the deducted conclusions rely on
VMAT plans of various treatment localizations which are not marked in the final results.
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Figure 4.7: Results of the gamma rates of the DQA measurements versus the definition
given by Masi (2013).
4.2.6 Unbalanced dosimetric distribution between the two arcs
Since no investigated modulation factor showed a clear correlation with the failure of
the DQAs, it was decided to pick one reference case and conduct a more detailed study.
This case failed the DQA and no reasonable explanation could be found. A simple re-
optimization was done, i.e. no parameters were changed. The newly calculated plan
passed the DQA without any issues. None of the definitions above showed a considerable
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difference. Comparing the two plans’s characteristics, it was found that the re-optimizing
improved the dosimetric distribution between the two arcs, i.e. both arcs were meant to
deliver equally around 50% of the prescribed MUs. Before the re-calculation the first arc
delivered 7.87% more of the planned MUs and the second arc just filled the missing dose for
completion of the plan with slightly higher modulation factors (ct. table 4.1). In a quick
check, several other unbalanced treatment plans were found that did not pass the gamma
criterion as well, but there were a few balanced plans that also did not pass. Therefore,
this as well seems not be a valid excluding criterion. It might prove to be a fruitful starting
point for another through examination in the future.
Table 4.1: Comparison of the differences between the first and the second arc for the
original plan, which failed the DQA and the re-optimized one passing it.
Original [%] Re-Optimized [%]
Total MU 7.87 0.81
Total Gy -7.00 7.16
StdDev DR 48.19 1.34
MFTomo -8.13 -1.08
MFTravel,arc 3.13 8.57
MFTravel,CP 4.38 11.11
MFWebb -7.08 -4.91
MCSarc 2.40 5.92
4.3 Summary and conclusion
The topic of modulation in external beam radiotherapy is not a trivial problem. Modern
techniques provide numerous degrees of freedom to achieve the desired dose distribution,
which makes it difficult to combine them to one single parameter. Multiple institutions are
currently working on the issue with inconclusive results. The presented work showed that
there is neither a clear correlation nor a threshold value for prostate cases treated with
dual arc VMAT plans between the magnitude of the modulation and the DQA result as
represented by the indexes studied here.
A reason for this could be that prostate cases are generally speaking rather low modulated;
this is confirmed by the obtained results. Including other, more complex treatment sites
- e.g. head and neck - might show certain tendencies. Additionally, an adaptation of the
action level triggered by the gamma passing rate might be a good idea. The task group
report 119 of the American Association of Physicists in Medicine (Ezzell et al. (2009)) is
recommending to reduce the passing rate down to 90% for a treatment stop based on their
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results for small field IMRT measurements with ionization chambers applying a criterion
of 3%/3mm. Furthermore, our study was of retrospective nature based on the measured
DQA and the theoretical plan data. It is possible that something unforeseen happened
during the DQA delivery, which forced the treatment control console to adapt at least
one characteristic parameter of the modulation, e.g. reduce the gantry speed, and thusly
creating a complete new scenario.
It could be beneficial to normalize the modulation factors, e.g. by their total prescribed
dose, to get a more independent basis for comparisons. Further work in the future is to
consider more statistics, i.e. creating a bigger sample size and database of numerous treat-
ment sites. One should also study the effect mentioned in the last section. It seems that
the way of the optimization plays a role in the modulation by influencing the dosimetric
distribution on the arcs.
While writing this thesis, a new article was published presenting an approach of phan-
tomless IMRT DQA (Valdes et al. (2016)). It is a theoretical calculation considering 78
uncertainties of metrics that might influence the DQA result. The most influential factors
are:
1. Amount of MUs per Gy
2. Number of small apertures
3. Aperture irregularity
4. the fraction of beams delivered outside circles of specific radii
These results confirm our findings that dosimetric and geometric data of the beam needs
to be investigated. Instead of the performance of the leaves it seems to be more important
to consider the actual beam shape and its irregularities.
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Uncertainties in TomoTherapy
In comparison to conventional linear accelerators the TomoTherapy units are rather new.
Their advanced features are very similar to the approach of VMAT: The accelerator is
rotating around the patient while applying the planned irradiation. With the introduction
of the helical TomoTherapy another degree of freedom was created, since - in addition to
the accelerator - the treatment couch moves as well.
The new factor setting the two movements in correlation is called pitch and indicates the
distance the treatment couch traveled in one gantry period. At the time of the introduc-
tion of TomoTherapy it was new as well that the treatment couch itself was able to correct
rotational displacements of the patient in relation to the planning kVCT. Already knowing
about the complexity of moving leaves in combination with a moving accelerator, one can
imagine the new level of modulation by adding a moving and rotating patient.
Due to the CT-like structure of a TomoTherapy unit only a small number of studies were
done using film dosimeters, diodes or 2D arrays replacing the patient to investigate the
uncertainties occurring in TomoTherapy treatment deliveries. However, we still depend on
unknown factors in real treatment conditions:
"We plan, do the DQA, and send the patient in, hoping for the best, knowing that un-
determined uncertainties are occurring" - A medical physicist and former TomoTherapy employee
In-vivo dosimetry (IVD) is a possible approach to find out what happens during a
treatment delivery. IVD applies a detector of choice measuring the dose while the patient is
treated. On the one hand the clinical staff can detect errors, both statistic and systematic,
of each fraction and on the other hand they can use the IVD system to evaluate and check
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the used machine and the treatment chain in general.
In cooperation with 21st Century Oncology (Madison, Wisconsin, USA), two software
applications were developed to recover and examine all relevant data of the actual treatment
delivery. These tools were introduced into the clinical routine for both TomoTherapy units
at the Institut Curie as well as tested in real clinical conditions over 18 months in the case
of "TomoGamma" and 4 months in the case of "TomoAdaptive".
Thanks to the results obtained with these applications, we conduct in chapter 5.6 a first
comprehensive study on uncertainties in TomoTherapy by analyzing the results of transit
in-vivo dosimetry and machine data of actual clinical cases. Furthermore, it is presented
how the tools can be used in daily clinical routine as a first approach towards adaptive
radiotherapy.
5.1 Materials & Methods
5.1.1 TomoTherapy
The experiments related to this chapter were done using two TomoTherapy R©Hi·Art ac-
celerators. TomoTherapy units were developed as a CT-Scanner-like machine with an
embedded acceleration line that can provide energies used in regular radiotherapy. The
linear accelerator is underneath a closed housing rotating around the treatment couch (ct.
fig. 5.3) allowing following treatment modes:
• TomoDirectTM, where the accelerator is set to a fix angle and does not move while
the radiation is applied. It is equivalent to step’n’shoot IMRT in terms of the low
level of modulation.
• TomoHelicalTM. Here, the gantry rotates and applies radiation to the patient, who is
lying on a moving treatment couch. Due to the capability of creating high modulated
plans, this modality can be compared to VMAT.
The accelerators at the Institut Curie produce photons of a nominal energy of 6 MeV at a
nominal dose rate of 850 MU/min (System (2011)). The energetic output of the gantry is
measured, amongst others, by three transmission ionization chambers placed between the
patient and the accelerator. They are hermetically sealed dual chambers with a precision
and linearity of 1% each. They can trigger beam-off safety protocols by monitoring, e.g.
the dose. Hereafter, these detectors will be called the "head detectors". It is worthwhile
mentioning that these chambers are not being used to control the duration of a treatment
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delivery. In conventional LINACs the length of a fraction is determined by the amount
of dose being measured by the on-board system. This approach is necessary, since with
this type of accelerators the energy and dose rate can change from plan to plan. With
TomoTherapy these two factors are meant to be constant and the duration of a treatment
is thus defined by the integration of time. Therefore, the consideration of uncertainties is
also different.
Normally, the data specifying a treatment plan is saved in DICOM format, where they
can be accessed by e.g. control points as mentioned above. However, in the case of
TomoTherapy the data is stored differently. Since the accelerator rotates several times
around the patient it is too difficult to distinguish the multiple gantry positions of the same
angle. Instead the system provides what is called a plan sinogram. The rotation leads
to numerous (several hundreds or even thousands depending on the irradiated volume),
so called, dose projections from different angles creating a sinus shaped curve if plotted
together (ct. figure 5.1). In a plan sinogram the leaf number is shown against the dose
projection number. The color scale is giving the time that a leaf is open in seconds, which
is, due to the constant energy and dose rate, a direct indicator of the dose. As such the
sinogram is the equivalent of a 3D dose map in space and time.
Figure 5.1: Example of a plan sinogram from an actual spine case. One can see sinus
shape of the curve. In the 3D plot the x-axis is the dose projection number (in total more
than 3000), the y-axis the leaf number of the MLC and the color indicates how many seconds
a leaf was open.
One of the unique characteristics of the Tomo units is the capability of reconstructing
a full CT with energies in the range of MeVs, thus called MVCT, verifying the patient’s
position referring to the planning kVCT prior to the beginning of a treatment. This MVCT
is recorded by a special designed arc-shaped detector rotating with and always opposing
the linear accelerator. With the development of the TomoTherapy machines the detectors
changed as well leading to different detector models available for a unit (ct. table 5.1).
Their advantages in comparison to EPIDs are their fixed positions, thus eliminating the
positional uncertainty of the detector. Since the detector has a different curvature than
the bore of the Tomo unit, it is important to consider the different structure, because the
obtained signal needs to be corrected to achieve the actual beam profile.
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Figure 5.2: The uncorrected signal of the arc detector measuring the profiles of the three
possible open fields in TomoTherapy. Due to the different curvature of the detector than
the LINAC rail a dip occurs for the center channels, which is amplified by the non.coplanar
fan beam. c©Pisaturo et al. (2015)
Table 5.1: Several generations of detectors are available having different characteristics
as shown below. The detector used for this thesis was of the third generation (bold text and
framed).
Detector 1 Detector 2 Detector 3 Detector 4
width of detector element [cm] 0.1219 0.118 0.12503 0.1242
radius of curvature [cm] 110.99 98.6 99.8 139.6
detectorSurfaceToAxisDistance [cm] 56.95 47.3 57.2 54.6
detectorSurfaceToCenterDistance [cm] 2 0 0.4 0
lowChannelOpenField 56 60 26 30
HighChannelOpenField 595 579 553 549
The only common point between all detectors is that each detector arc is consisting of
certain number of Xenon-gas filled chamber divided into several chambers by septal plates.
The used units were equipped with the detector given in the third column.
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Figure 5.3: Image of a Tomotherapy unit indicating the rotating linear accelerator un-
derneath the housing. And the opposing detector arc. c©Accuray Inc.
Another advantage, especially from a scientific perspective, is that all treatment infor-
mation is stored in a log file in XML format that is automatically created when archiving
the patient. All major patient and machine data are stored in it, such as the machine
output, gantry speed, patient setup, patient setup corrections etc. Even more information
can be downloaded directly after each treatment from the system by a ftp connection as
a CSV-file, e.g. gantry angle per projection, chamber signal per projection, cooling water
temperature..
Another unique fact in comparison to LINACs is the binary MLC. Binary already indicates
that each leaf can have only two states: open or closed. They are driven by hydraulic forces
using air pressure. Available field sizes are 1cm, 2.5cm, and 5cm for each of the 64 leaves.
Since the binary mode restricts the capability of modulation, a new modality called
TomoEdgeTMwas developed. It is not included in this work, as it was not available in
our clinic.
The used software version controlling the Tomo units and planning was version 5 (build:
5.0.2.26, planning station 5.0.2.5).
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5.2 System description of "TomoGamma" and "To-
moAdaptive"
5.2.1 "TomoGamma"
The first of the two programs is called "TomoGamma". Its aim is to check all the technical
aspects of a treatment such as machine output, patient positioning, comparison between
reference kVCT, and actual MVCT.
The data is collected by the detectors built into a TomoTherapy unit: three overhead
ionization chambers for the dosimetric output and the MVCT imaging detector facing the
LINAC. Furthermore, the TomoSystem itself records machine data: among others, the
gantry angle of each dose projection, the adjustment of patient positioning prior to the
treatment. All these data are stored in the patient archive, which can be retrieved at any
time via a ftp connection.
The archive is imported into a directory constantly scanned by "TomoGamma" to initiate
all the necessary calculations as soon as a new archive is available. For example a gamma
analysis for each projection transforming the analyses to a 3D gamma passing rate, making
it possible to locate the point of failure within the patient’s CT to analyze if a certain local
anatomical structure or change is responsible for a low gamma passing rate. This detection
is already the first step of adaptive radiotherapy, because it is detecting the influence of
anatomical changes that require a re-planning fraction by fraction.
The passing rate is created by calculating the differences between the analyzed treatment
fraction and a reference fraction, which is by default the first one but can be changed
to any available fraction of the plan. The passing rate is calculated for each of the dose
projections, usually 51 per rotation, and then averaged over all projections. The results
are available in coronal, sagittal, and rotational perspective.
The gamma value calculation is based on the pixel values of the projection’s image reg-
istered by the imaging MVCT detector. These values do not contain direct dosimetric
information; hence, an comparison of absolute dose, e.g. to the plan, is currently not pos-
sible.
Only a relative gamma comparison of two fractions is available at this point, as the cal-
culations are based on the pixel values of the projection’s image recorded by the imaging
MVCT detector. These values do not contain direct dosimetric information. The default
gamma criterion is set to 3%/3mm and the passing rate to 95% of the pixels having a
gamma value ≤ 1, but these values can be changed to any value at any time for all pa-
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tients, one single plan, or even for only one fraction.
Based on the measured output, one can determine the dose rate by multiplying the output
value with a constant factor proprietary to 21st Century Oncology. The two CTs, planning
kVCT and MVCT of a fraction, are merged and superposed in different coloring highlight-
ing any differences to the anatomy and positioning recorded during the reference treatment
fraction. Additionally, the two CTs are compared to each other based on pixel intensities.
A factor called "Similarity" quantifies any difference between the images ranging from 0 to
1, where 1 is a perfect match of the CTs and 0 indicates that not a single matching pixel
could be found.
Figure 5.4: Treatment result dashboard of a radiotherapy plan in "TomoGamma". It
shows the analyzed parameters, i.e. patient positioning (translation, rotation), anatomical
changes by comparing the planning kVCT and daily MVCT (similarity), machine output
(outputMean, outputVar), and the global gamma result. The thresholds for each column
are given in the table above the results. A deeper analysis of each fraction can be done by
selecting on the corresponding link in the second column.
In the context of clinical routine, a considerable amount of time is spent to analyze the
obtained results, even though mostly failing fractions are of interest. Thus, a three-colored
based warning system was introduced in the general overview to speed up the evaluation
process. It shows the amount of all fractions delivered to the patient and their rated results.
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Table 5.2: Flagging criteria for all calculated factors for analyzing the treatment’s quality.
Gamma
Passing
rate [%]
Similarity Output
Variance
Output
Mean
Translation
Offset
[cm]
Rotation
Offset [◦]
Green >97.5 >0.95 <0.03 <0.015 <1 <3
Yellow (97.5,95) (0.95,0.9) (0.03,0.06) (0.015,0.03) (1,2) (3,5)
Red <95 <0.9 >0.06 >0.03 >2 >5
5.2.2 "TomoAdaptive"
Since "TomoGamma" is restricted to technical machine data and allows neither a compar-
ison in absolute dose nor a comparison of the measured results to the planned data; an
additional tool was developed with 21st Century Oncology: "TomoAdaptive".
The idea is to use both programs as complementary tools. "TomoGamma" indicates that
one or multiple technical factors failed during a treatment and "TomoAdaptive" assesses
the clinical impact done from a dosimetrical perspective.
Once again the user only needs to push the patient archive to the incoming folder if he
desires to start the adaptive calculation manually. As, at the Institut Curie, we use both
applications, it was possible to provide certain automation to the process. The files were
exported once to "TomoGamma". As soon as "TomoGamma" is finished with its analyses,
the files will be pulled by "TomoAdaptive" automatically to start its calculations. The soft-
ware then retrieves the necessary information. This includes the planning kVCT, planned
sinogram, contoured structures, prescribed dose, planned dose distribution, and the MVCT
of each fraction.
"TomoAdaptive"’s aim is to assess the success of a treatment delivery through several
data:
• It shows a merged CT of the planning kVCT and the MVCT of the analyzed fraction
to detect major anatomical changes.
• Data of the original plan: the kVCT superposed by the planned dose distribution
and original ROIs.
• The daily MVCT superposed by the deformed ROIs. The deformation is calcu-
lated by using the image intensity based Morphon’s algorithm (Latifi et al. (2013),
Wrangsjö et al. (2009), Forsberg et al. (2007), Plumat et al. (2009)).
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• As additional layer in this view the changed dose distribution is calculated, caused
by the change in the anatomy with the help of the extracted plan data. The dose
calculation is performed by a collapsed cone convolution-superposition algorithm
(Ahnesjö (1989), Oyewale (2013)) and is a complete re-calculation.
These datasets are now utilized to derive even more information for each contoured
ROI, which helps to assert the quality of the treatment:
• Received dose based on the deformed information compared to the plan, both for
each fraction and cumulative.
• Dose-Volume-Histogramm (DVH), both for each fraction and cumulative.
• Changes in volume of the ROI.
• Position of the ROI’s centroid to estimate organ movement.
In order to guarantee a correct analysis, it is important that the investigated structure
is sufficiently imaged, at least 95%, during the daily MVCT. It is clear that a DVH, position
data, and volume information are incorrect if parts of the volume are - or rather cannot -
be considered in the calculation due to missing information.
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a) b) 
c) d) e) 
f) g) 
Figure 5.5: The "TomoAdaptive" dashboard for a breast patient plan. The upper part
shows the DVHs of the three selected ROIs (a), and b)). The lower part represents the rest
of the information such as volume (f)), displacement (g)) or imaged percentage (e)) for
the ROI "PTV Sein G", which is the target volume in the left breast. Additionally, one can
change to the comparison of the four CT windows in "Fxs viewer" or "Cumulative viewer".
In the main window on the top the DVHs are shown. The left one (a)) displaying the
result of the selected fraction (here no. 18, selected with the slider below the DVHs). It
displays
• The planned DVH (solid line)
• Per fraction results, i.e. of the deformed ROIs and the dose distribution on the
MVCT (symbols)
• The DVH based on the deformed ROIs mapped back to the planning CT (dashed
line)
The right graph (b)) is depicting the cumulative DVH up to the moment of the selected
fraction. Again presenting
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• The planned DVHs (solid line)
• The DVHs based on the information of the deformed ROIs mapped back to the
planning CT (dashed line)
Down below one can investigate further information:
• Dose trend fraction by fraction (c))
• Cumulative dose trend (d))
• Imaged percentage (e))
• Volume change (f))
• The displacement of the geometrical center of a ROI (g))
Since the data is written in HTML5 it is easy to open and transfer and allows to retrieve
data of specific points by hovering the mouse over the graph (ct. figure 5.5 in the graph of
"Imaged percentage", where the cursor hovered over the 13th fraction).
5.3 Assessing the sensitivity of "TomoGamma"
Although having an application based on approved and routinely used methods, it is nec-
essary to verify if the information given is correct and has a sufficient sensitivity, especially
when they are used in a novel implementation that never was done before. Thus, several
tests with different levels of complexity were created to benchmark the software.
Three different phantoms (TomoPhantom, also referred to as the "cheese", the RANDO
phantom, and the CIRS Thorax) are being irradiated in helical TomoTherapy. The phan-
toms themselves pose certain challenges. The Cheese is cylindrical and can be homogeneous
or heterogeneous by inserting plugs with different electron densities.
The Rando head is homogeneous but is irregularly formed with proportions of a real hu-
man head. The third phantom is heterogeneous and imitates the difficult scenario of a
thoracic treatment, e.g. breast cancer. In addition, several changes within the planning
are applied: simple cylindrical targets in the center and off center overlapping with the
heterogeneities, as well as ring structures around the center. More detailed information on
the test geometries will be given in the corresponding sections for a better overview.
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(a) (b) (c)
Figure 5.6: The three phantoms used to characterize the software’s limitations: The
"cheese" (a), the RANDO head phantom (b) c©Radiology Support Devices, and the CIRS
Thorax (c) c©Supertech.
For the purpose of testing "TomoGamma", each case will consist of several fractions
including the reference, i.e. correct setup and kVCT identical density configuration, and
fractions with a changed setup, e.g. shifted in all three dimensions and in rotation.
Furthermore, anatomical variations, i.e. reduction of a bolus from 3cm to 0cm and addition
of heterogeneities are introduced from fraction to fraction. The bolus simulates a change
in the patient’s anatomy.
The dose variation is verified by comparing it to an absolute dose measurement recorded
with an ionization chamber A1SL (Standard Imaging). In order to detect even smaller
differences a sensitive gamma of 2%/ 2mm is applied and the passing rate is set to 95%.
The created plans for the cheese and the RANDO were calculated to apply a total of 120
Gy in 60 fractions to the target volume. For the CIRS phantom a plan following the in-
house standard for breast treatments was created including the present OARs in a breast
case, such as the lungs, the heart, the spine, and others. The protocol prescribes 51.8 Gy
in 28 fractions to the PTV.
Despite the greatest effort to perfectly recreate the phantom’s position in the planning CT,
there will always be some minor differences. The results of the dosimetric analysis and the
CT comparison are normalized to the values of the reference fraction to account for these
deviations.
5.3.1 Results
5.3.1.1 CIRS phantom
The phantom was contoured following the different structures as present in a breast case
created by the varying densities within the phantom. It is provided with a drilling to
insert an ionization chamber. Several layers of bolus material were laid upon the "breast"
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to simulate a loss of volume during the treatment course. The layers have a thickness of
0.5cm and were removed one after the other.
Table 5.3: The results of the measurements using the CIRS phantom with stepwise bolus
reduction. The differences (∆) are normalized to the reference fraction.
Bolus
reduction [cm]
Measured Dose
[cGy]
Passing rate
[%]
∆passing rate
[%]
∆dose,chamber
[%]
0 188.53 99.99 0.00 0.00
0.5 190.33 98.04 1.95 0.96
1 190.33 90.51 9.48 0.96
1.5 193.95 83.97 16.03 2.88
2 196.36 79.74 20.26 4.15
The table above shows that the gamma evaluation is failing at a reduction of the
thickness of 1cm by lowering the passing rate by 9.48%, whereas the ionization chamber
measured only a difference of less than 3%. Thus, "TomoGamma"’s sensitivity is higher for
volume changes in the direction of the beam. Even the reduction of 0.5cm leads already to
a decrease of 2% of the passing rate, whereas the mean dose in one point does not measure
a significant difference.
Using the obtained results as fixing points for functional fit, it can be concluded that a
change 0.7cm will lead to red flagged gamma and already a change >0.5cm will lead to a
passing rate lower than 97.5% which is the threshold for the warning level (yellow flag).
5.3.1.2 RANDO phantom
The RANDO phantom was shifted by 10mm and 20mm in all three dimensions. Addi-
tionally, a rotational shift of 10◦ and 20◦ was tested separately. A comparison with the
ionization chamber could not be done, since the phantom has no cavity to insert one.
Additionally the similarity checks of the CTs were analyzed.
The cylindric PTV had a diameter of 2cm and a length of 2cm and was placed above the
OAR. An organ at risk of 3cm in diameter and 6cm in length was placed at the center of
the phantom.
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Table 5.4: Results of "TomoGamma" with the RANDO phantom applying directional and
rotational shifts. In addition to the passing rates the similarity values of the CT comparison
were included.
Shift direction Shift [mm] Passing Rate [%] CT Similarity [%]
Reference 0 99.86 0.98
Transversal 10 96.57 0.9120 94.09 0.84
Longitudinal 10 99.71 0.9420 97.88 0.88
Vertical 10 97.36 0.9120 94.80 0.85
Rotation 10 97.94 0.9620 94.95 0.92
With the exception of the shift in longitudinal direction, the directional shifts of 20mm
and the rotation of 20◦ lead to failing gamma passing rates, whereas the shifts of 10mm/
10◦ triggered the warning level in the best case or remained undetected by the gamma
analysis in the worst case. This is due to the homogeneous nature of the phantom, since
there are not a lot of dosimetric differences with smaller shifts when the photons are still
attenuated by the same material. Especially moving the phantom in longitudinal direc-
tion, i.e. orthogonal to the beam, with a cylindrical phantom will not create a dosimetrical
change. The similarity values of the CT signaled a problem by failing their passing criteria
of 0.95 at a shift of 10mm.
By creating a curve fit, it was concluded that "TomoGamma"’s sensitivity of directional
shifts in transversal direction is 18mm and for rotations it is 19 ◦ relying only on the gamma
passing rate.
The sensitivity increases by 13mm by taking the CT comparisons into account. Thus,
shifts larger than 5mm and rotations larger than 13 ◦ will be flagged with a failure even in
homogeneous conditions.
After testing the detection sensitivity of the gamma criterion and the similarity value
separately, the following experiments with the cheese phantom will consider these criteria
in combination and stepwise change the complexity of the scenario.
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5.3.1.3 Cheese phantom with an homogeneous configuration
Centered targets with no OAR
The first plan of the homogeneous setup targets at a PTV volume in the center of the
phantom. It has a diameter and length of 3cm each and serves as a GTV. A second target
is placed at the center as well and is a cylindrical ring structure around the GTV with an
inner diameter of 3cm, an outer diameter of 6cm, and a length of 6cm serving as the PTV.
The total dose prescribed to the second target was 108Gy. No OARs were introduced.
This test is the most challenging one for "TomoGamma". The phantom is homogeneous
and circular symmetric, such as the target volume. Hence, all beaming directions will be
equally weighted and small differences in the position are not expected to have a big impact
on the dose distribution.
Table 5.5: Results of the cheese with homogeneous setup and two centered target volumes.
Shift
direction
Shift
[mm]
Measured
dose [cGy]
Passing
rate [%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
Reference 0 203.34 99.92 0.99 0.00 0.00
Transversal 6 205.43 99.62 0.97 0.30 1.0315 195.85 99.20 0.94 0.73 3.68
Longitudinal 6 203.04 99.89 0.99 0.03 0.1515 200.04 99.82 0.99 0.11 1.62
Vertical 6 201.84 99.66 0.97 0.26 0.7415 204.84 99.03 0.94 0.89 0.74
As described above, this is the most challenging setup for "TomoGamma". Therefore,
it is no surprise that most of the shifts remained undetected, except for the transversal and
vertical shift of 15mm, where the CT similarity started to flag a problem. The ionization
chamber measured a difference larger than 2% only for the transversal 15mm shift.
The sensitivity of "TomoGamma" is superior to the point measurement of the ionization
chamber. The CT comparison parameter created a warning at a shift of 6mm in both
transversal and vertical direction. As concluded from a curve fit based on the results of
the similarity factor, shifts bigger than 12mm will be failing the comparison criterion.
Centered PTV with two off-center OARs
The next test with the homogeneous configuration included a PTV at the center of the
phantom with a diameter and a length of 6cm each. The two cylindrical OARs had a
diameter and length of 6cm as well. Using the phantom’s center as origin of a Cartesian
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coordinate system the OARs’s centers were placed at (5.66cm, 5.66cm) and (-5.66cm,
5.66cm). The objectives for the OARs were a maximal dose of 30Gy for the first one and
40Gy for the second one.
Table 5.6: Results of the test case with a homogeneous configuration of the phantom. The
dose of the centered target had to be achieved by sparing the two off-centered OARs.
Shift
direction
Shift
[mm]
Measured
dose [cGy]
Passing
rate [%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
Reference 0 203.34 99.94 0.99 0.00 0.00
Transversal 6 202.15 99.73 0.97 0.21 0.5815 200.37 99.53 0.94 0.41 1.46
Longitudinal 6 203.34 99.91 0.99 0.04 0.0015 203.34 99.82 0.99 0.13 0.00
Vertical 6 203.93 99.84 0.97 0.10 0.2915 203.93 99.61 0.94 0.34 0.29
Rotation 10 203.34 99.88 0.99 0.06 0.0020 203.34 99.85 0.99 0.09 0.00
The results show almost the same tendency as before, only the 15mm shifts in transver-
sal and vertical direction created a failing value of the CT similarity comparison. Since
there are no changes in the density, a small change in the dose distribution was not ex-
pected to create greater errors. The ionization chamber did not even measure a single
difference larger than 2%.
Disturbing the equivalent beam weights does not seem to improve the detection threshold.
As a next step the symmetry will be broken by moving the PTV out of the center.
Off-centered PTV and centered OAR
As the last test using the homogeneous setup, a PTV was placed at (5.66cm, 5.66cm) with
a diameter and length of 4cm each. The centered OAR is the previous used target at the
center with a planned objective to not receive more than 30Gy. Since the first experiments
did not reveal errors in the gamma analysis it was decided to shift the phantom by 20mm
and 25mm in transversal, 20mm and 40mm in longitudinal, and 20mm and 30mm in
vertical direction. The rotational difference to the reference fraction was set to 15◦ and
35◦. By doing so, it was expected to obtain at least one data point failing the gamma
passing criterion.
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Table 5.7: Results of the cheese phantom having an homogeneous setup. This time the
target was shifted to a position with 8cm distance to the phantom’s center at an angle of
45◦.
Shift
direction
Shift
[mm]
Measured
dose [cGy]
Passing
rate [%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
Reference 0 203.81 99.96 0.99 0.00 0.00
Transversal 20 195.42 90.08 0.92 9.88 4.1225 187.63 88.69 0.91 11.28 7.94
Longitudinal 20 203.81 99.92 0.99 0.04 0.0040 67.14 99.75 0.99 0.21 67.06
Vertical 20 196.62 90.29 0.93 9.68 3.5330 139.67 87.83 0.90 12.14 31.47
Rotation 15 201.42 99.88 0.99 0.08 1.1835 82.72 99.91 0.99 0.05 59.41
The greater shifts lead, as expected, to gamma failures in transversal and vertical
direction. However, "TomoGamma" was not able to detect any change in longitudinal
direction, whereas the ionization chamber detected the shift of 40mm. The smaller rotation
remained undetected in all conducted measurements. Only the ionization chamber was able
to detect the change of 35◦. "TomoGamma" had a better sensitivity for all shifts, except
for the rotations, the greater vertical, and the greater longitudinal shifts.
In general, the gamma analysis failed when the measured dose exceeded a difference of 2%
as well, except the 40mm longitudinal shift.
The results of the fit can be found in table 5.15.
5.3.1.4 Cheese with a heterogeneous configuration
The next three tests were performed with the following density variations: air (0g/cm3),
adipose tissue (0.943g/cm3), breast tissue (0.980g/cm3), and inner bone (1.152g/cm3). The
configuration can be seen in figure 5.7.
These tests are closer to real scenarios, since the human body consists of a variety of
different tissues and structures with varying electron densities. Due to the latter, the
penetrating photons have more or less interactions with the matter and thus it is expected
smaller variations of the test setup will be detectable.
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Figure 5.7: The configuration of the density plugs used in the tests of the heterogeneous
setup of the cheese phantom.
Off-centered PTV, three OARs
For the first test a cylindrical target with a diameter and length of 6cm each was created. It
was positioned at (5.66cm, 5.66cm). Two plugs were contoured as OARs plus an additional
cylindrical OAR at the center having a diameter and length of 6cm each. The PTV does
not overlap with the heterogeneities.
Table 5.8: Results of the test with an off-center positioned target and three cylindrical
OARs. The OARs and the target are not overlapping.
Shift direction Shift [mm] Passing Rate [%] CT Similarity [%]
Reference 0 99.89 0.99
Transversal 10 98.59 0.9620 89.91 0.92
Longitudinal 10 99.45 0.9920 99.04 0.99
Vertical 10 93.29 0.9620 86.91 0.93
Rotation 10 99.34 0.9920 98.72 0.99
The larger shifts of 20mm in transversal and vertical direction could be detected by the
gamma analysis and the CT comparison. Additionally, the 10mm displacement in vertical
direction was flagged red. The CT similarity already created a warning signal for the minor
shifts in both transversal and vertical direction.
Applying a curve fit, it was concluded that shifts larger than 15mm in transversal and 8mm
in vertical direction can be detected by the gamma analysis. The sensitivity of the CT
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comparison is 12mm in both directions. The values of the ionization chamber are missing,
since it was broken at the time of the measurement.
Off-centered PTV, three OARs
The next test is almost identical to the previous one, but with the important change that
the target is now at (-5.66cm, 5.66cm), thus overlapping with the inserted heterogeneities.
This setup and configuration simulates the worst case scenario, since the unexpected change
in anatomy is happening at the primary location of the dose distribution. Thus, minor
changes should have greater influences on the planned data.
It was decided to decrease the step size in this test, since it is posing the biggest medical
challenge. That is why it is important to know when which factor starts to signal an error.
Table 5.9: Results of the test with an off-center positioned target and three cylindrical
OARs. The heterogeneities and the target are now overlapping.
Shift
direction
Shift
[mm]
Measured
dose [cGy]
Passing
rate [%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
Reference 0 88.66 99.87 1.00 0.00 0.00
Transversal
5 93.23 95.81 0.98 4.06 5.15
10 96.28 91.20 0.95 8.68 8.59
15 99.32 88.19 0.92 11.70 12.03
20 104.20 86.01 0.90 13.87 17.53
Longitudinal
5 75.56 99.88 1.00 0.01 14.78
10 57.77 99.77 0.98 0.09 34.85
15 41.56 94.18 0.95 5.69 53.13
20 23.64 83.24 0.91 16.65 73.33
Vertical
5 93.23 98.51 0.98 1.36 5.15
10 95.67 96.13 0.95 3.74 7.90
15 98.10 93.87 0.93 6.01 10.65
20 97.49 91.68 0.90 8.20 9.97
Rotation
10 72.51 93.28 0.98 6.60 18.21
20 59.23 89.61 0.97 10.27 33.20
30 50.94 88.66 0.96 11.22 42.54
40 43.99 89.65 0.97 10.23 50.38
As expected, smaller errors in positioning can be detected with heterogeneities in the
target volume. All changes in the rotation were detected. In transversal direction the 5mm
shift was not red flagged but is already down to a passing rate of 95.8%. The ionization
chamber was capable of detecting already the smallest applied variation and had a better
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sensitivity throughout the whole test.
Once again doing a curve fit, the following detection thresholds could be determined:
Table 5.10: Failure thresholds for the experiment where the target volume is overlapping
the heterogeneities.
Transversal
[mm]
Longitudinal
[mm]
Vertical [mm] Rotational [◦]
Gamma
analysis
6 15 13 7
CT similarity 10 15 11 40
Adding heterogeneities without displacements
The ROIs, their contours and the positions, remained unchanged in comparison to the
previous setup. In order to test the detection efficiency with heterogeneities, density plugs
of air and lung tissue, and a bolus of 2cm where added to the phantom. These tissues were
selected since the observed anatomy changes are mainly respiration motion and changes in
bowel gas.
These changes where measured individually and combined to see to which extend density
changes have to be present for detection.
Table 5.11: Results of the experiments where at first single heterogeneities were inserted
and then in combination. No positional shifts were applied.
Heterogeneity
insert
Measured
dose [cGy]
Passing rate
[%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
none 112.58 99.86 1.00 0.00 0.00
Air 116.84 98.57 0.99 1.29 3.78
Lung 111.97 99.06 0.99 0.80 0.54
Lung+Air 116.84 97.42 0.99 2.44 3.78
Bolus 2cm 102.24 81.50 0.98 18.38 9.19
Lung+Air+Bolus 106.50 89.25 0.98 10.63 5.41
One can see that neither air nor lung tissue create a failing gamma passing rate. Only
when the bolus is added to the setup the gamma analysis is signaling a failing analysis.
The ionization chamber was able to detect the air gap and its combination with the lung
density plug. However, "TomoGamma" proofed to have a better sensitivity in all other
cases, although the CT comparison could not signal one single density variation.
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5.3.1.5 Test series adding a bolus
Observing that the bolus has the biggest influence in the previous gamma analysis, it was
decided to do an extra test series investigating its impact in more detail on the homogeneous
cheese phantom.
Centered PTV, 2 off-centered OAR
The centered PTV has a 3cm diameter and a length of 3cm as well. The two OARs are
at the coordinates (5.66,5.66) and (-5.66,5.66) having both a diameter and length of 6cm
each.
Table 5.12: Results of the experiments using the homogeneous setup of the cheese phantom
in combination with bolus reductions. The PTV is positioned at the center and there are
two OARs at 8cm distance from the center at an angle of 45◦ and 135◦.
Bolus
reduction
[cm]
Measured
dose [cGy]
Passing rate
[%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
0 201.51 99.83 0.98 0.00 0.00
1 202.76 99.38 0.98 0.46 0.62
2 205.25 97.13 0.97 2.70 1.86
3 208.37 93.36 0.97 6.47 3.41
In comparison to the heterogeneous CIRS phantom (ct. table 5.3), where bolus dif-
ferences of 0.7cm could be detected, the flagging with the homogeneous cheese begins at
2.6cm, which again can be explained by the small dosimetric changes with a homogeneous
setup. Even the ionization chamber only has a difference larger than 2% at the reduction
of 3cm.
Speaking of general sensitivity, "TomoGamma" is better in detecting the changes already
giving a warning at a reduction of 2cm.
Centered PTV, cortical bone heterogeneity
The test setup remained mainly unchanged. Only a density plug having the same electron
density as a cortical bone was inserted as heterogeneity.
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Table 5.13: Results of bolus reduction on a homogeneous cheese phantom with a cortical
bone heterogeneity.
Bolus
reduction
[cm]
Measured
dose [cGy]
Passing rate
%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
0.00 207.24 99.95 0.99 0.00 0.00
0.50 212.62 100.00 0.98 0.05 2.59
1.00 217.40 98.61 0.96 1.34 4.90
1.50 223.37 95.92 0.95 4.04 7.78
2.00 229.34 92.34 0.94 7.61 10.66
2.50 235.91 88.55 0.93 11.41 13.83
3.00 241.88 85.61 0.92 14.35 16.71
One can see that adding only one heterogeneity already increases the detection effi-
ciency, since a bolus reduction of 1.6cm will fail the gamma analysis. The warning level of
the similarity parameters is decreased to a bolus reduction of less than 1cm.
The ionization chamber had a better sensitivity to the changes in all applied reductions.
Centered PTV, cortical bone heterogeneity, displacement
As a final test it was investigated how "TomoGamma" would react to a bolus reduction
with heterogeneities present and arbitrary displacements. This scenario reproduces the
realistic conditions of daily treatments.
Table 5.14: Realistic reproduction of treatment deliveries: The bolus is reducing, while
the phantom is moving with heterogeneities in the radiation path.
Bolus
reduction
[cm]
Shift
(x,y,z)
[cm]
Measured
dose [cGy]
Passing
rate [%]
CT
Similarity
∆passing rate
[%]
∆dose,chamber
[%]
0.00 (0,0,0) 207.49 99.76 0.98 0.00 0.00
0.50 (4,0,3) 209.28 99.84 0.97 0.07 0.86
1.00 (2,0,7) 206.29 99.27 0.96 0.49 0.58
1.50 (5,0,3) 200.31 98.40 0.94 1.36 3.46
2.00 (4,0,4) 171.01 96.99 0.92 2.79 17.58
Although a gamma failure could not be provoked in this test, "TomoGamma" is still
sufficient enough to detect changes as soon as the ionization chamber due to the CT
comparison. Even the ionization chamber could not detect a smaller reduction either,
whereas the similarity parameter at least signaled a warning.
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5.4 Considerations of the sensibility of "TomoAdap-
tive"
During this work, we did not assess the influence of uncertainties on the sensitivity of
"TomoAdaptive" due to time constraints, because we preferred to go on and test clinical
cases.
Still, it is recommended in future work to conduct the following tests:
• A physician should approve the changes of the ROI geometry done by the deformable
registration.
• Although 21st Century Oncology validated the dose calculation against the TPS of
TomoTherapy, the information given in the DVHs should be verified by comparing
the dose information to measurements of an ionization chamber for various setups.
5.5 Summary of the assessment
Table 5.15 summarizes the thresholds for failing gamma analyses derived from the curve
fits based on the previously presented tests. Additionally, some warning thresholds creat-
ing a yellow flag are shown below in the table for the test cases closest to real treatment
scenarios.
In homogeneous setups, the gamma analysis may not have enough sensitivity. It indicates
a problem starting with shifts bigger than 1cm in the best case and theoretically 2m,
based on the curve fit, in the worst case, which is larger than the treatment couch itself.
Nevertheless, "TomoGamma" is performing well by using the similarity parameter, which
creating a warning starting with shifts bigger than 5mm. In comparison to an ionization
chamber, "TomoGamma" had a better sensitivity in the homogeneous test series.
Introducing heterogeneities, the gamma analysis is more reliable in detecting shifts. It cre-
ates a warning with shifts larger than 6mm, whereas the CT comparison is able to detect
a difference starting with 10mm. Although, "TomoGamma" was not as sensitive as the
ionization chamber in these tests, it is still sufficient by at least creating a warning signal,
when the chamber measured a bigger difference than 2%.
In the last test measurements with a bolus "TomoGamma"’s sensitivity is comparable to
the ionization chamber’s detection efficiency.
As overall conclusion, it can be stated that "TomoGamma" is sensitive enough for ap-
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plication on clinical cases as long as all provided parameters are considered. By doing so,
one is able to detect treatment errors caused by heterogeneities, positional or anatomical
changes as efficient as with an ionization chamber.
Furthermore, it is recommended to use a gamma criterion of 2%/2mm, since the acceptance
of bigger differences will probably lower the sensitivity to the centimeter-range.
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5.6 Assessing uncertainties with the help of "To-
moGamma"
Equipped with a good in-vivo dosimetry (IVD) system, one can now start further inves-
tigations on uncertainties present during TomoTherapy treatment deliveries to see how
stable a treatment plan is over time and to see the influence of uncertainties.
5.6.1 Fraction by fraction development of the passing rate
It is too complicated to perform daily IVD with conventional linear accelerators. Setting
up the measurement, even using the EPID, takes too much time and the following analysis
occupies the physicist for a long time. That is why, at the Institute Curie, IVD on c-arm
accelerators is only done the first three fractions and then once per week, although it is
advised to do it more frequently (Celi (2016)).
The benefit of "TomoGamma" is that all these processes are automated and done in the
background without additional workload during the treatment delivery. Therefore, daily
delivery checks were implemented to answer the following questions concerning the general
development of the delivery:
1. Are there substantial changes in the gamma passing rate, i.e. in the quality of the
treatment delivery, both between consecutive fractions and between the first and last
fraction?
2. Is it possible to determine a certain fraction number when a general revision of the
delivery plan should be done?
The gamma passing rates of all investigated fractions were extracted using an in-house
developed extraction program written in Matlab. The study comprised both matched
TomoTherapy units and all tumor localizations. Thus, 359 RT plans of Tomo1 and 227
plans of Tomo2 were included. Two tests were done:
• All fraction numbers were averaged to create one average "plan". From this plan the
gradient of a trend line was calculated.
• A trend line of each single plan was calculated and their gradients were then averaged.
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5.6.1.1 Results
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Figure 5.8: Results of the averaged gamma results of Tomo1 (a) and Tomo2 (b).
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Table 5.16: Results of the different obtained gradients evaluating the development over
time of the gamma analysis. maveraged fractions is giving the gradients obtained by applying
a linear fit to the averaged gamma passing rates of each fraction. m¯ is the average of all
gradients calculated for each plan.
maveraged fractions m¯ m<0 -0.5<m<0.5
Tomo1 0.02 -0.28 72.42% 76.32%
Tomo2 -0.09 -0.4 79.74% 72.25%
The linear fits of the averaged fractions show a low gradient. The one of Tomo1 is even
positive due to the low sample size of plans having more than 35 fractions and the ones
existing have a high passing rate.
Calculating the gradient of the plans individually and taking their average leads to different
results: Both are negative and multiple times steeper. Tomo2 has more plans that have a
negative gradient than Tomo1 and the averaged passing rates are lower in general. This
might be caused by two factors. Although both units are matched in their output, they
are used to treat different tumor localizations. Tomo2 delivers radiation to more complex
cases like head and neck or pelvic tumors, whereas Tomo1 primarily treats prostate cases.
The other reason might be that Tomo2 was more unstable than Tomo1. Reasons for the
instability will be discussed in the next chapter.
In order to answer the questions mentioned above, it can be stated that there are no
substantial differences in the passing rates and no fraction for general revision were found;
although, it might be worth to check the behavior of the Tomo2 plans starting with fraction
17, i.e. after the delivery of around 50% of the planned fractions.
5.6.2 Machine Output
The reliable production of x-rays is a critical part of radiotherapy. Its procedure is strongly
dependent on the digital and mechanical parts within the accelerator. It is thusly essential
to test the machine output on a daily basis to verify whether the output is within the
tolerance limits of the reference data. Additionally, other checks have to be done on a
regular basis, called machine quality assurance (machine QA), ensuring that there are no
major issues when starting a treatment.
However these measurements give a general overview and cannot assure that any error will
occur at another point in time. After observing several failing DQAs, one can say that
these failures seemed to occur sporadically, i.e. measuring the same plan a second time
lead to passing DQAs. It was assumed that there is a problem with the output, but it was
neither possible to reproduce the failing situation nor to verify the assumption.
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Upon introducing "TomoGamma", it was noted that the first investigated cases had several
failing fractions, with a passing rate lower than 95%. As mentioned above, "TomoGamma"
is capable of extracting the machine output of each dose projection and calculating the
dose rate. A further investigation showed that the majority of the failing plans did not
pass the outputMean and sometimes the outputVar criteria (ct. table 5.2). Furthermore,
it was observed that the dose rate drops considerably below the planned value probably
causing the low passing rate, since the output and as such the applied dose was too low
(ct. figure 5.9(a)).
Installing "TomoGamma" made it possible to find the root-cause of the existing problem
of the QA at Institut Curie. In parallel, the vendor developed a system to control the
machine output: The Dose Control System (DCS).
The DCS is a servo based closed loop control (Staton et al. (2012)) on the machine output.
It employs the two built-in head ionization chambers as feedback sensors. Then, the out-
put and as such the dose rate is stabilized by adapting the LINAC’s accelerating current,
so that the dose rate drift should not occur anymore (ct. figure 5.9(b)). An analysis was
conducted comparing gamma passing rates before and after the installation of the DCS to
verify the feature and as well to estimate how big the influence of the drop in the output
was.
(a) (b)
Figure 5.9: Results of the dose rate analysis of the same patient and same plan prior the
DCS installation (a) and after it (b). dose 1 (red, solid line) and dose 2 (green, dashed
line) are the data of the overhead ionization chambers and reference (blue, dashed line) is
the planned value.
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5.6.2.1 Application on clinical cases
A total of 161 patients with different treatment sites were included in the study, therefrom
43 prior and 118 posterior to the installation of the DCS, leading to a total of 4253 analyzed
fractions (1144 prior and 3109 posterior to the DCS installation).
The planned and delivered dose rate, and gamma passing rates were extracted from "To-
moGamma" using an in-house written software created in Matlabr, which as well calculated
the analyses.
Based on the previous assessment, it was decided to set the gamma criterion to 2%/2mm.
The passing rate remains unchanged at 95%.
5.6.2.2 Results
When comparing the results of the two patient groups, the average gamma passing rate
moved from 90.90% prior to the installation up to 94.79% after the upgrade of the Dose
Control System. The average deviation of the measured dose rate compared to the planned
value was 2.44% prior to DCS vs. 0.17% post DCS installation. This difference is smaller
than expected and may be due to the fact that - in the absence of the DCS - the dose rate
could shift. Depending on the magnitude of this shift, it may lead to a failure of the plan
in IVD. Nevertheless, there is an obvious correlation between the deviation of the dose rate
and the gamma passing rate: 60.18% of the plans have a passing rate superior to 95% with a
variance of 10.69 after the DCS upgrade in contrast to 27.91% passing plans and a variance
of the gamma analysis of 56.33 before the DCS. This is well reflected in our exemplary case
from figure 5.9. Even with a routine gamma analysis of 3%/ 3mm the fractions prior the
DCS upgrade have an average gamma passing rate of 59.85% and an average intra-fraction
variance of the dose rate of 4.76 [MU/min]2. After the installation, the average passing
rate increases to 97.43% with an intra-fraction variance of 2.13 [MU/min]2. In terms of
differences to the planned dose rate, the value decreases from 4.25% to 0.08%.
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Figure 5.10: Results of the study investigating the influence of the dose rate drift on
the gamma passing rate. Shown are the averaged passing rates prior (a) and posterior (b)
the DCS installation of the analyzed plans. Please note the different scale on the
x-axis. For the results after the upgrade the highest data point’s value is even smaller than
the smallest value for the cases prior the installation.
As can be seen in figure 5.10, the gamma passing rate clearly decreases as soon as the
deviation of the dose rate exceeds 2%. The newly installed DCS prevents this by keeping
the deviation below 0.5%. The upgrade is thus doubling the passing rates and decreasing
the variance of the dose rate to a fifth.
When focusing on a single patient affected by the dose drift, one can see that a possible
underdosage could be prevented and gamma passing rates decreased above the passing
criterion by using the DCS system.
Analyzing the causes of all failing gamma analyses, the dose drift is throughout the leading
error source causing gamma passing rates below 95% for 25-83% of the analyzed fractions.
In figure 5.11 one can see the influence in a direct comparison of failing fractions including
and excluding cases where the drift was the primary error source.
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Figure 5.11: Shown is the influence of the dose rate drift (DRD) on the uncertainties
for different tumor localizations. The uncertainty introduced by the drift is reduced to
50% using the DCS. For eye and rectal treatments at Tomo 2 it even drops to 0. Please
remember that the units treat different locations, thus the x-axis in 8a9 and (b) is different.
5.6.2.3 Discussion
With the help of "TomoGamma", it was shown that the Dose Control System is an impor-
tant tool ensuring the quality of a treatment by stabilizing the machine output avoiding a
potential underdosage of the target volume. The uncertainty based on the machine output
could be reduced to 50%.
5.6.3 Additional uncertainties in TomoTherapy
Once we managed to remove the leading source of uncertainties of our TomoTherapy units,
namely the machine output, a further analysis could focus on additional sources affecting
the gamma analysis.
In order to do so, "TomoGamma" was applied on both TomoTherapy units leading to a
total number of 577 RT plans (363 of Tomo 1 and 208 of Tomo 2) with various treatment
sites. Each treatment site has its own set of error sources due to different heterogeneities
or irregularities of the body.
The root-causes were assessed for each failing fraction; the conclusion was noted down in
a summary table for all treatment sites, resulting in an overview of how often which un-
certainty caused a gamma failure. Table 5.17 shows the results of the leading uncertainties
sorted by main clinical localization assessed with "TomoGamma".
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Table 5.17: Final overview of the leading sources causing gamma passing rates below
95%. Combination expresses that at least two possible causes could be found. The dose
rate drift (DRD) is in an extra column, since it is not occurring anymore, but was the
leading cause before the DCS upgrade. The other columns show the results, when the DRD
could be excluded as leading error source. The percentage value gives the proportion of red
flagged plans caused by the corresponding source after the DCS installation.
Tomo 1 Tomo 2
Primary
error source
Secondary
error source
DRD Primary
error source
Secondary
error source
DRD
Breast Respiration
(19.44%)
Combination
(13.89%)
47.00% Breast too
big to be
reliable
reposi-
tioned/
anatomy
change
(9.09% +
9.09%)
Combination
(9.09%)
72.73%
H&N Combination
(45.83%)
Dental
Implants
(25.00%)
29.17% Anatomy
change
(50%)
N/A 50.00%
Spine/
Brain
Anatomy
change incl.
Bowel gas
(50.00%)
Combination
(25.00%)
25.00% Combination
(50%)
N/A 50.00%
Pelvis Combination
(25.00%)
Anatomy
change incl.
Bowel gas
(14.28%)
57.14% Anatomy
change
(16.67%)
Combination
(8.33%)
75.00%
Lung Combination
(25.00%)
N/A 7.00% Anatomy
change
(75%)
N/A 25.00%
Eye Anatomy
change
(50.00%)
N/A 50.00% N/A N/A 100.00%
Rectum Anatomy
change incl.
Bowel gas
(100.00%)
N/A N/A N/A N/A 100.00%
Other Combination
(8.33%)
Error in
position
(8.33%)
83.33% Hip
implants
(25%)
Combination
(25.00%)
50.00%
Prostate Hip
implants
(25.00%)
N/A 75.00% N/A N/A N/A
In most of the cases, not a single uncertainty lead to the failure of the gamma analysis
but rather a combination of at least two factors, e.g. weight loss of the patient combined
with respiratory motion.
81
5. Uncertainties in TomoTherapy
Metallic implants lead to artifacts in the radiologic images, thus disturbing the gamma
analysis, so the information given by "TomoGamma" is not reliable.
Considering the respiratory motion it was observed that the gamma failure is often in the
low dose region at the border of the body, e.g. the upper shoulder, but the gamma analysis
in the region of the treatment volume was passing.
Knowing the leading error sources, it is possible to develop and introduce new localization-
specific measures to reduce their influences on the quality of the treatment delivery. "To-
moGamma" can help to assess their efficiency by continuously checking comparing the
gamma analyses.
5.7 Oﬄine Adaptive Radiation Therapy: Consid-
erations of the use of Tomoadaptive and "To-
moGamma" in clinical routine
Adaptive radiotherapy (ART) has been a difficult task, because many factors needed to
develop to a certain point, e.g. computational power including parallel computing on GPUs
for fast calculations for an affordable price or communication interfaces between treatment
machine and analyzing software/ stations.
In order to fully implement ART in clinical routine, following criteria have to be fulfilled:
• Daily 3D-CT being registered to the planning kVCT allowing deformable registration
to detect anatomy changes.
• Organ segmentation on the daily MVCT for updated DVHs.
• Dose calculation on daily MVCT to estimate what actually happened during the
fraction (hotspots/ coldspots)
• Automatic workflow to minimize occupation of staff and allowing for time consuming
calculations being performed in the background 24/7.
It is clear that "TomoGamma" and "TomoAdaptive" have the potential to offer the
opportunity to start trials to do ART. For a practical protocol all patients being treated
should be archived at least once every day. It is advised to archive treated patients twice
per day, e.g. just before lunch break and after the last treatment, to ensure that results
are ready the next day.
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Alternatively, a recommended use case could be: The first "TomoGamma" results should
be present within a few minutes after archiving the files. Then, one can check if there is
an error leading to failing gamma passing rates and if these are being caused by technical
sources, e.g. machine output or error in patient set-up.
One can review the DVHs in "TomoAdaptive" for the same fraction if no explanation could
be found and then assess whether the dosimetric difference might be critical. Possible
explanations might be found in changed patient anatomy, which can be checked in "To-
moAdaptive" as well. Additionally, it allows seeing if the anatomical changes lead to critical
hotspots in organs at risk or cold spots within the target volume.
Finally, with all these information one can decide whether replanning is necessary or not.
The overall workflow is shown in figure 5.12.
First fraction 
applied, patient 
archive exported 
to TomoGamma 
Check in TomoGamma if 
red flags are present. If 
so analyze if technical 
error occured, e.g. 
machine output 
Could the 
problem 
be found? 
Take action as 
seems fit 
Start TomoAdaptive 
Review DVHs – Are 
there dose differences? 
Check patient set up in 
transversal, coronal, 
and sagittal view 
Check patient‘s 
anatomy. e.g. in merged 
CT or volume/ centroid 
position graph 
No 
YES Is it clear if 
action is 
required? 
Take action as 
seems fit 
Review 
cimulative DVH if 
dose differences 
are critical 
No 
YES 
Figure 5.12: Possible workflow of adaptive radiotherapy using "TomoGamma" and "To-
moAdaptive".
Up to this point, the additional workload is within an acceptable limit. The export
process can be a batch process. The calculations are then started automatically and it is
only necessary to take some time to review the results.
However, should replanning be necessary, the workload increases exponentially due to
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safety protocols leading the treatment chain to start from scratch: A new planning CT has
to be done, new contouring, a new plan, all signatures by physicians and physicists, and
finally another DQA before the new plan can be applied.
The question to be answered in the future is: How big must the difference be to justify
replanning?
It is clear that the implementation of Adaptive Radiotherapy in routine requires speed
and automatization. First developments already go into this direction, e.g. automated
contouring or automatically setting the treatment plan objectives in the TPS. Another
good approach to speed up the DQA measurement is the proposed approach of phantom-
less DQA (Pisaturo et al. (2015)). The procedure works without setting up, and positioning
a phantom and dosimetric utilities leaving out the warmup phase and measuring the back-
ground noise. Thus, only the actual radiation time is remaining.
5.8 Summary and Conclusions
The aim of this chapter was to assess globally the uncertainties present in TomoTherapy.
After successfully benchmarking the important tool, it was possible to get an idea what is
actually happening during a treatment delivery. It was found that, based on all analyzed
characteristics, one is capable of detecting changes in the position of 5mm when the first
warning in form of a yellow flag is created. Position shifts of larger than 10mm will create
a critical alert using a gamma criterion of 2%/ 2mm.
Verifying the treatments on a daily basis, it can be seen that the dosimetric output of the
machine was not sufficiently stable. The dose rate drift was not big enough to provoke an
emergency stop by the interlocks regulated by the head chambers. Nevertheless, it was
big enough to lead to multiple failures in the gamma analysis, and therefore indicating a
potential underdosage. Seeing these effects, it seems vital to upgrade a TomoTherapy unit
with the Dose Control System to avoid single cases affected negatively by the DRD. Using
"TomoGamma", it was proven that the DCS is working well and reduces the variation of
the output to a minimum.
With the biggest uncertainty eliminated, a broad study of uncertainties with reference to
specific tumor localizations could be done. Two major sources leading to low passing rates
are anatomical changes of the patient, e.g. different amount of bowel gas or size of the
bladder between single fractions, and combination of two or more uncertainties, e.g. a big
breast which is difficult to reposition and respiratory motion.
Being aware of the leading causes of gamma failure, one is now able to go further and to
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adapt the existing safety protocols, e.g. gas releasing rectal balloons for prostate cases.
Finally, it was shown how tools like "TomoGamma" and "TomoAdaptive" can be developed
further to implement adaptive radiotherapy in clinical routine. The checks of the treatment
delivery can be done fast and easily due to the automated flagging system. The next step
will be to create new protocols and infrastructures to speed up the process of replanning.
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Chapter 6
General Conclusions and Outlook
As mentioned in the introduction, uncertainties occur along the complete workflow a pa-
tient undergoes when treated in external beam radiotherapy. This work approached some
of them in the three main sections: pre-treatment QA, assessing overmodulation during
the delivery, and IVD in TomoTherapy as a follow-up of a treatment delivery.
Initially, we demonstrated that assessing the quality and accuracy of the QA measurement
chain plays a major role in further understanding other sources of uncertainties in radiother-
apy. It was shown that the angular dependency of 2D chamber arrays is a non-negligible
effect affecting the measurement equipment. The presented approach for TomoTherapy
units is performing a theoretical synchronization of the measured snaps with the gantry
angle by introducing a virtual gyroscope. Despite the positive results, one might argue
if the synchronization is good enough. A bigger sample size of patients will verify the
fail-safety of the algorithm. Though, it might be beneficial to use the proposition of phan-
tomless DQA directly using the built-in detectors as proposed by Pisaturo et al. (2015)
and lately developed by 21st Century Oncology. Such a solution is improving the position
uncertainty of the detector and the angular dependency. It would be mandatory though
to periodically verify the detector signal quality.
The assumption that the modulation of dual arc VMAT prostate cases causes DQA failures
was not be completely confirmed. The results showed that the investigated cases have a
rather low modulation, hence other tumor localizations should be included in future stud-
ies. Publications studying a variety of tumor sites came to the conclusions that there is also
no clear threshold marking an overmodulation (Masi (2013), Celi et al. (2015)). However,
they found a tendency between the modulation and the DQA/ IVD results. Due to the
large interest in investigating the complexity of treatment plans, it might be only a matter
of time when a suitable factor can be confirmed. The publication of Valdes et al. (2016)
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shows that the tested parameters are playing a role but need to be assessed and combined
in a different way.
The last chapter introduced a new framework for IVD in TomoTherapy. It is based on the
information collected by the on-board detectors and protocols and calculates amongst oth-
ers a local gamma analysis. This application, "TomoGamma", provides useful information
to assess if an error occurred during a treatment delivery. The sensitivity of "TomoGamma"
is good enough to detect 0.5cm positional shifts if a gamma criterion of 2%/2mm is used.
Applying the program in clinical routine it was possible to detect the root-cause of failing
DQAs, namely the dose rate drift. After the installation of the Dose Control System, "To-
moGamma" could confirm the improvement on the machine output, practically eliminating
it as one of the leading error sources.
Furthermore, "TomoGamma" was used to create a first comprehensive summary of root-
causes of delivery failures and to derive their influence on the treatment quality for a group
of representative clinical localizations. Additionally, a second application was introduced in
clinical routine: "TomoAdaptive". Both work complementary: "TomoGamma" is detecting
a problem with a treatment delivery and "TomoAdaptive" is utilized to assess the clinical
impact and if a replanning is necessary. This combination is laying the foundation of the
introduction of adaptive radiotherapy in TomoTherapy, since it is assessing each treatment
fraction automatically day-by-day.
As soon as the validation in clinical conditions of the deformation algorithm of "TomoAd-
aptive" is done, further investigations will be completed. One example might be a study
of the volume change of, e.g. the breast, during radiotherapy application. Interfraction
uncertainties, like the organ motion, can be assessed easily by extracting the information
of the output file provided by "TomoGamma".
The presented work showed multiple uncertainties and how they can be assessed, resolved,
or at least mitigated. As such, it aligns with the works ongoing in parallel in multiple
institutions and publications on the subject. New technologies and techniques will come
with new uncertainties or they will make it possible to be more accurate and reducing un-
certainties. "TomoGamma" and "TomoAdaptive" are a good example of how new solutions
can identify treatment problems to improve them increasing the treatment quality.
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